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Over seven million Americans suffer from Chronic Venous Insufficiency (CVI), a painful 
and debilitating disease that affects leg veins.  Problems associated with CVI include 
varicose veins, bleeding, ulcerations, severe swelling, deep vein thrombosis, and 
pulmonary embolism, which may lead to death.  The presence of CVI is the result of 
damaged one-way vein valves, or incompetent valves, in leg veins.  When normally 
functioning, these valves allow forward flow of blood to the heart, and prevent pooling of 
blood at the feet due to gravitational forces.  However, as vein valves degrade in older 
patients, incompetent valves allow reflux of blood, and cause clinical problems.  There 
are few effective clinical therapies for treating CVI and certain treatments require the 
valve to be replaced. Vein valve transplants are surgical options for treatment.  However, 
it is often difficult to find suitable donor valves within the same patient.  Prosthetic valves 
have been developed in the past, but none have demonstrated sufficient clinical or 
mechanical functionality.  Persistent problems include thrombus formation, valves that 
leak when backpressure is applied, and valves that do not open with a physiologic 
pressure gradient, which is typically less than 5 mmHg.  The primary objective of this 
research was to develop a functional prosthetic vein valve for treating patients suffering 
from CVI.  Additionally, this research proposes engineering design requirements for a 




The novel prosthetic valve is flexible, biocompatible, has low thrombogenecity, and is 
easy to manufacture.  It was designed to address well-defined consumer needs and 
functional design requirements.  The valve was required to 1) withstand 300 mmHg of 
backpressure with less than 1.0 mL leakage per minute, 2) open with a pressure gradient 
less than 5 mmHg, and 3) meet criteria 1 and 2 even after 500,000 cycles of opening and 
closing in simulated physiologic conditions.  Bench testing demonstrated that the valve 
met these three critical design requirements.  The valve can open with pressure gradients 
as low as 2.0 ± 0.5 mmHg, and can withstand 300 mmHg with a leak-rate less than 0.3 
mL/min.  The valve remained functional even after opening and closing over 500,000 
times.  The valve burst at a pressure of 530 ± 10 mmHg, six times greater than 
physiologic pressure.  The valve presented in this research is operationally functional, 
and shows good potential as a solution to treating deep valvular incompetence in CVI 













Chronic Venous Insufficiency 
Over seven million Americans suffer from Chronic Venous Insufficiency (CVI), a painful 
and debilitating disease that affects the venous system of the lower extremities [1]. The 
presence of CVI is usually the result of incompetent, or malfunctioning, one-way valves 
in leg veins.  Incompetent valves cause 80 to 90 percent of CVI cases involving venous 
reflux [2].  The one-way valves in leg veins are critical for proper circulation because 
they prevent blood from pooling at the feet due to the force of gravity.  In normal 
physiology, the calf muscle contracts during leg movement and squeezes blood upward 
through the valves.  Using this muscle action of the calf, sometimes referred to as the 
“peripheral heart,” the body is able to overcome gravitational forces to maintain blood 
flow back to the heart.  However, in pathologies involving CVI, the leg veins and valves 
do not maintain proper blood flow to the heart, leading to a host of clinical problems.   
 
Problems associated with CVI include varicose veins, ulcerations, bleed, and swelling, as 
well as more severe cases involving Deep Vein Thrombosis (DVT) and Pulmonary 
Embolism, which usually leads to death.  Over 300,000 patients in the U.S. are affected 
annually by DVT [3, 4], and the total cost for treating these patients is estimated over $2 
billion per year [5].  CVI tends to affect older patients, and with a growing population of 
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the elderly in developed countries, the incidence of CVI is likely to increase 




             
 
Figure 1: Ulcerations (left) and varicose veins (right) caused by vein valve 
incompetence.  Note the severe swelling of both legs, due to hypertensive conditions.  






Etiology of Chronic Venous Insufficiency 
There are two processes by which CVI arises; one involves the aging process, the other 
involves formation of an obstruction that damages vein valves.  Venous incompetence 
that is the result of natural aging is often referred to as primary incompetence, while 
secondary incompetence refers to pathologies involving obstruction or destruction of the 
valve.   
 
Primary incompetence develops as the structural composition of veins change. In an 
aging vein wall, the intima thickens and elastin fibers and muscle layers become 
disorientated and disorganized. Elastic lamina within the intima becomes more 
fragmented, atrophic, thin, and irregular [6].  Reduced elastic lamina in aged veins makes 
it more vulnerable to high pressure-distention.  As veins distend, valves also distend, to 
the point where the leaflets within the valve no longer meet in the lumen to seal properly.   
 
Secondary incompetence occurs when vein valves are destroyed, with leaflets becoming 
adherent, folding over, and being absorbed into the vein wall [7].  The incidence of 
secondary incompetence has been reported as high as 95% in patients having ulcerations 
and deep venous reflux [8].  Valve damage often occurs due to thrombus formation [9].  
The valve leaflet pockets are the primary region of thrombus formation [10].  Poor 
sealing of valves leads to regurgitation and turbulence of blood flow, as well as areas of 
stagnant blood flow, increasing the likelihood of thrombus formation.  This thrombus 
growth can then lead to the destruction of the afflicted vein valve.  The absence of one 
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vein valve results in additional pressure applied on the next valve distal to the missing 
valve, and the process of vein distention and valve destruction cascades down the leg.   
 
Other processes that lead to valvular incompetence and CVI involve vascular trauma, 
tumor growth, and also thrombus formation unrelated to valvular abnormalities, such as 
Deep Vein Thrombosis (DVT).  Patients with a history of DVT have over a 25-fold 
increase chance for developing CVI compared to patients without a history of DVT [11]. 
 
Vein Structure and Mechanics 
Veins, like arteries, have three main layers comprising the vessel wall.  The inner-most 
layer is in contact with blood, and is called the tunica intima.  The intima is very thin and 
contains fragmented elastic media [6].  Surrounding the intima is the second layer, the 
tunica media.  The media has three distinguishable layers, with the innermost layer 
containing longitudinal muscle fibers, interconnected with elastin fibrils and connective 
tissue.  The middle layer contains wide bundles of smooth muscle cells (SMC’s) in 
circular orientation separated by elastic fibrils.  The outer later contains longitudinally-
orientated muscle bundles and fibrous tissue.  Surrounding the vein media is the 
adventitia, which contains connective tissue, nerve fibers, and vasa vasorum. 
 
The compliance of veins is very different from the compliance of arteries. Arteries have 
low distensibilty at low intramural pressures, and continue to be distensible even at high 
pressures.  However, veins are highly distensible at low pressures, and distention ceases 
when intramural pressure reaches approximately 50 mmHg, with diameter expansion 
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limited to 1.5 to 1.6 times the original vein diameter (Figure 2) [12, 13].  The 
arrangement of various elastin and collagen fibrils, as well as the different muscle 
structure of vein walls, all contribute to the unique mechanics of veins.  It is paramount 
that any prosthetic vein valve design accommodates vein distensibility appropriately.  A 
prosthetic valve that is flexible may be ideal valve for vein distensibility.  
Accommodating vein distension will help minimize trauma to the vein, improve comfort 
for the patient, and may reduce the risk of inflammation or thrombus formation in the 

























Vein, from Stooker et al, 2003
Human Saphenous Vein, from
Wesley et al, 1975
 
 
Figure 2: Human veins distend very easily at low pressure (less than 50 mmHg), and are 





In the legs, there are three venous networks that work in conjunction with each other to 
advance blood upwards to the heart.  The deep venous system consists of veins of large 
diameter that lie deep underneath the muscles of the leg, close to the bones.  The tibial 
vein is a deep vein found in the calf, which turns into the popliteal vein located just 
behind the knee.  The popliteal vein then turns into the femoral vein which is located in 
the thigh, leading to the iliac vein and eventually the inferior vena cava.  The superficial 
venous system consists of small diameter veins that are found just below the surface of 
the skin.  Connecting the superficial veins to the deep veins are perforating veins.  All of 













Table 1: Average occurrence of valves in deep veins [14] 
 
Deep vein # of valves 
Common femoral vein (above sapheno-femoral junction) 1 
Femoral vein (below sapheno-femoral junction) 3 
Popliteal vein 1 
Posterior tibial vein 19 
Anterior tibial vein 11 




There are two types of vein valves in legs: ostial valves and parietal valves.  Ostial valves 
are positioned at the entry of a smaller vein branch into a larger vein, and aid in 
distribution of blood throughout the leg during leg muscle contractions.  Parietal valves 
are generally positioned just proximal to a venous junction, within the larger vessel of the 
junction.  Parietal valves are the main pressure-bearing valves, and are the more critical 
valves involved in CVI and surgical procedures.   
 
Valve Function 
Vein valves function by allowing antegrade (forward) blood flow to the right atrium of 
the heart, while preventing retrograde (reverse or reflux) flow to the feet.  A functioning 
valve thus exhibits two very important characteristics: patency and competency.  A valve 
that is patent remains open during antegrade flow, free of obstruction or occlusion.  A 
valve that is competent seals appropriately during physiologic reflux, preventing 
backwards flow of blood.  Figure 4 depicts the difference between a valve that is 
competent and patent and a valve that is incompetent and obstructed. 
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Figure 4: Competent and patent valves (left) and obstructed and incompetent valves 




Different vein valves open at different times through calf pump cycle [8]. During 
compression of the calf, deep vein valves open while valves in the perforating veins and 
valves distal to the location of muscle compression close.  This synchronous opening and 
closing of valves channels blood not only towards the heart, but ensures blood is 
channeled to the deep veins [9].  During a regular walking cadence, the calf muscle 
pumps approximately 40 times a minute.  Typically with each calf pump, the blood stroke 
volume is 10 to 20 mL [9].   
 
It is important to note that vein valve function differs from heart valve function due to the 
different hemodynamic environment.  Heart valves operate in high pressure, high flow 
environments, while vein valves experience a lower pressure, lower flow environment.  
Heart valve closure is driven primarily by flow, while vein valve closure is instigated by 
a drop in sinus pressure.  The low flow environment in the venous system creates 
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opportunity for red thrombus to form.  This imposes different challenges for an implanted 
medical device than the challenges normally faced in an arterial system.   
 
Valve Anatomy 
A native vein valve has several distinguishing features that play important roles in its 
function.  Vein valves can have anywhere between one and five leaflets that coapt in the 
lumen of the vein to form a sealing valve.  However, generally vein valves are bi-leaflet.  
The valve orifice is elliptic in nature, with an opening area about 35% of the full luminal 
area [15].  Veins tend to be elliptical in cross-section, due to the muscular pressure within 
the legs.  Valve leaflets are also orientated such that longitudinal major axis follows the 
circumference of the deep fascial cross-section.  Physiologic valves are capable of 
withstanding very high proximal pressure gradients with minimal leakage, and can open 
at very low distal pressure gradients.  When a person is standing or sitting, the leg vein 
valves are open, allowing forward flow of blood.  Thus venous pressure equals pressure 
from column of blood from point of measurement to right atrium of heart [16, 17].  
However, when a person is or walking or suddenly stands from a sitting position, valves 
are opening and closing with each muscle movement.   
 
Valve leaflets range in thickness from about 20 to 50 microns, and are composed of 
collagenous fibers covered with two unicellular endothelialized layers.  One cell layer 
forms the parietal side, which faces proximally towards the valve sinus.  The other cell 
layer faces the distal lumen.  The parietal side contains some small ridges, while the 
luminal side of the leaflet is generally very smooth [14].  The commissure is the contact 
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point of the leaflets, and the region of each leaflet between the commissure and the vein 
wall is referred to as the cornua.   
 
The leaflets are parabolic in shape, and connect to the vein wall via the valvular agger, a 
thickened protrusion of the vein wall.  The agger acts as a stiffening collar to prevent 
excessive vein dilation at the site of the leaflets (Figure 5) [14].  This helps limit vein 
distension to the sinus region.  The media of the vein wall in the sinus region is only 20 to 
25% as thick as the media of the vein wall elsewhere [18].  This allows localized sinus 






Figure 5: Anatomy of bi-leaflet vein valve [14].  1) orifice  2) sinus pocket  3) valvular 




Valve Sinus and Vortical Flow 
Recent studies have explored the importance of the sinus in the function of vein valves.  
When the valve is open, central axial flow goes through the orifice.  Flow separation 
occurs at the leading edge of each of the leaflets, and reattaches at the walls of the sinus, 
creating a vortex in each sinus pocket.  The streamlines of the vortex travel down the wall 
of the sinus, up the parietal side of the leaflet, and meet the central flow just proximal to 





Figure 6: Vortical flow in valve sinus [15] 
 
 
Vortical flow applies pressure on the parietal surface of cusps; when this pressure 
balances pressure on the luminal surface of the cusp, the valves remain open in 
equilibrium.  Small perturbations in pressure, via muscle movement or changes in blood 
 13
flow, on either side of the cusp will cause oscillations of the leading edge of the cusps, 
while still in equilibrium [15].  
 
Studies in the late 1980’s and early 1990’s led to the thought that reflux flow greater than 
30 cm/s was required to close valves when subjects are in a supine position [19].  
However, more recently, Lurie et al indicated that reverse flow is not necessary for 
valves to close, but rather that closure “coincides with the decrease of the flow velocities 
and the ballooning of the sinus.” [20].   Results showed that reverse flow was absent 
through vein valves in 7 of 8 in situ cases.  Valves responded to small negative pressure 
gradients, and closed before reflux occurred.   
 
Lurie et al postulated that the ballooning of the sinus increased local pressure in the sinus 
due to decelerated flow.  They noticed that the sinus bulged in size and became more 
spherical in shape, and that rotating flow in the sinus keeps cusps away from walls.  Also, 
they observed that as antegrade flow slowed, the rotating flow in sinus slowed as well, 
and the pressure in the sinus started to close the valve before reflux could even occur 
[20]. 
 
Vortical flow is also thought to play an important role in preventing stasis of blood in the 
leaflet pockets, thus minimizing the potential of thrombus formation.  Coupled with the 
pulsatility of venous flow from the calf muscle pump, vortical flow acts as a natural 
purging mechanism for removing cellular aggregates from the leaflet pockets [21].  This 




Diagnosis of Venous Incompetence 
Patients considered for vein valvuloplasty (valve repair) have symptoms of severe venous 
insufficiency and leg discomfort.  Included amongst these symptoms are venous 
claudication, swelling, stasis dermatitis and ankle ulcerations [22].  Generally, the first 
phase of examination takes place in the office.  After examining symptoms and patient 
history, the surgeon will determine if non-surgical management can be pursued or if 
additional tests are needed.  Mild, uncomplicated varicose veins and telangiectasia 
(spider veins) can usually be treated without surgery [2].  If additional tests are needed, a 
non-invasive duplex ultrasound scan is usually the first vascular lab test conducted.   
 
An ultrasound scan allows the surgeon to evaluate the more superficial veins of a patient. 
During duplex scanning, the surgeon attempts to elicit venous reflux response, and does 
so using one of several experiments, including cuff deflation, the valvalva maneuver, and 
manual calf compression in the standing position.  Duplex scan shows sites of reflux and 
obstruction, and can help distinguish between superficial and deep problems [2].  
Additional conventional ultrasound testing techniques include B-mode, color, and pulsed-
wave Doppler scanning.  The surgeon may ask the patient to perform the Valsalva 
maneuver, which entails the contraction of abdominal and upper leg muscles to induce 
higher venous pressure.  The Valsalva maneuver accentuates venous problems, and is 
helpful for diagnosing incompetence at the more proximal vein valves.  Finally, air 
plethysmography can be a useful method to determine obstruction and reflux; however, 
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generally, plethysmographic techniques are helpful only for determining presence and 
severity, but not location or causality, of incompetent valves. 
 
After a patient is considered for a valvuloplasty or valve replacement, two tests are 
performed.  First, an ascending venogram is conducted to map out veins in leg, showing 
location of deep, perforating, and superficial veins [2].  The ascending venogram usually 
involves injection of a contrast media in the dorsal foot vein.  X-ray videography is used 
to image the flow of blood.  This test is considered the gold-standard for demonstrating in 
vivo patency of a valve.   
 
Secondly, a descending venogram will be performed to show the location of affected 
valves.  A descending venogram is considered the gold-standard for detecting deep vein 
thrombosis and incompetent valves of the deep veins.  For this venogram, contrast media 
is injected proximal to valve sites suspected to be damaged.  The descending venogram is 
about 90% accurate in differentiating primary from secondary incompetence [2].  Valves 
affected by primary incompetence will leak media through the leaflets, while valves 
affected by secondary incompetence allow full flow of media downwards (Figure 7).  It is 
important to differentiate the type of venous valve incompetence, as each type calls for 
different strategies of treatment.  Primary venous incompetence can be surgically 
corrected via a valvuloplasty.  It is much more difficult to correct secondary venous 
incompetence with surgery, mainly since the valves are destroyed beyond repair.  The 
subsequent section titled “Current Clinical Therapy and Treatment” will discuss options 






Figure 7:  Descending venograms of common femoral vein by Kistner et al [2].  Left 
picture shows fully competent valve, preventing contrast agent from flowing below 
valve.  Middle pictures shows valve having primary incompetence, where the valve cusps 
aren’t sealing properly, evidenced by the leakage of contrast media distal (below) the 
valve site.  Right picture shows entire post-thrombotic common femoral vein afflicted 
with secondary incompetence.  Note that the contrast agent is found throughout the entire 
vein, indicating valves are destroyed.   
 
Current Clinical Therapy and Treatment 
There are few effective clinical therapies for treating CVI.  Anti-coagulants, compressive 
hosiery, and bed-rest are non-invasive therapies that are typically used to help alleviate 
symptoms.  However, these therapies can be very frustrating for the patient, particularly 
since bed-rest and compressive hosiery constrain a patient’s lifestyle.  Also, these 
therapies target the symptoms of CVI, rather than rectifying the cause of CVI. 
 
There are several surgical options for treatment, depending on the severity and 
complexity of CVI in the patient.  For patients suffering from superficial venous 








incompetence, the affected veins can be stripped out.  Blood flow will collateralize into 
the remaining functional superficial veins, and will generally not adversely affect the 
patient.  This is a fairly common procedure, and can be done with minimally invasive 
techniques.  If perforating veins are incompetent, they generally need to be interrupted to 
isolate their incompetence [2].  Interruption is achieved by ligating (tying off) the veins 
with sutures.   
 
Surgical treatment for deep venous incompetence is a more complicated affair.  The 
superficial and perforating venous systems have multiple vessels that will collateralize 
blood flow in the event a vessel is interrupted or removed.  However, the deep veins are 
the main conduits of blood, and to remove or interrupt the deep veins is to essentially 
block blood from returning to the heart.  Because the deep veins must remain in the body, 
another surgical approach must be taken.   
 
Surgical treatment of the deep vein valves is dependent on the type of venous 
incompetence, primary or secondary competence, that afflicts the patient.  Primary 
incompetence results in general widening of the valve commissural angle and elongation 
of the valve leaflets, meaning the valve leaflets are not coapting properly.  Various 
surgical techniques can treat primary incompetence effectively because although the 
leaflets are deformed, the basic structure of the valve is intact [9].  This is evidenced by 
Ferris et al reported that after 4 years in femoral vein valve reconstruction patients, 70% 
of valve repairs were classified as “good or excellent” [23].  Surgical techniques used in 
such repairs include internal, external, and transcommissural valvuloplasty [24].  
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Valvuloplasty involves the strategic placement of several interrupted sutures where the 
valve leaflets join the vein wall, to help restructure the valve leaflets to their original 
anatomy.   
 
Secondary incompetence appears more commonly in patients than primary incompetence 
[9].  Since often paired with thrombus formation, secondary incompetence results in the 
destruction of valve leaflets [9].  In the deep venous system, the most common cause of 
reflux is post-thrombotic valve damage.  Some medical centers have reported as high as 
95 percent of patients with venous ulceration and deep reflux having post-thrombotic 
valve damage [8].  Venous reflux due to secondary incompetence is rarely surgically 
repaired, and when it is, the repair seldom lasts [2].  Effective treatment for secondary 
valvular incompetence requires that the valves be replaced.   
 
Valve Replacement 
There are two main options in deep venous valve replacement: 1) transplantation or 
transposition and 2) prosthetic implantation.  Taheri et al reported the first autologous 
vein valve transplant in a human patient in 1982 [25].  Transplantation is still used only 
in necessary cases, only after medication, physical rest and therapy, and other less 
invasive surgical procedures have been tried or considered.  Valve transplant or 
transposition can cause unnecessary trauma to the patient’s leg, and most procedures 
require indefinite post-operative anti-coagulation.  Problems arise even prior to surgery 
because it is difficult to find a suitable donor valve.  Since CVI is a systemic disease, the 
leg contralateral to the affected leg is usually afflicted with CVI as well.  Thus the 
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probability of finding a functional autologous donor valve in the contralateral leg is low.  
This is evidenced by the fact that 30 to 40% of axillary vein valves, which are often used 
for superficial femoral venous valve replacement, are found incompetent prior to 
harvesting [26].  One study showed that transplanted and transposed valves had long term 
patency rates of 37-100% and 17-66%, respectively [27].  Despite these complications 
and risks, autologous vein valve transplant is generally considered the most effective 
treatment for secondary valvular incompetence of the deep veins.   
 
In more recent years, a variety of mechanical and bioprosthetic implantable valves have 
been created and studied.  However, few have demonstrated clinical potential for 
humans, with most valves revealing problems of poor patency due to thrombotic 
occlusions and elicited immunogenic response.  In 1985, Hill et al reported designing an 
implantable venous valve similar to that of human anatomy.  Some valves were 
fabricated of Pellethane®, a polyurethane elastomer, while others were fabricated of 
gluteraldehyde-fixed umbilical cord segments.  Flow testing showed the valves opened 
with an applied pressure gradient of 4.5 mmHg.  Eight days after implantation in dogs, all 
implanted valves had occluded due to red thrombus formation [28].    
 
Also in 1985, Gerlock et al attempted using bioprosthetic cardiac valves as vein valves.  
Four gluteraldehyde-fixed pericardium annulus trileaflet valves coupled with Dacron® 
grafts were implanted into four dogs.  Ascending venograms revealed patency in all four 




Other research efforts have concentrated on designing mechanical vein valves.  In 1988, 
Taheri et al developed a bi-leaflet mechanical valve design.  They performed both in 
vitro and canine in vivo experiments on platinum and pyrolitic carbon-covered titanium 
valves [30].  After 16 weeks, six of ten valves remained patent and competent.  Those 
valves that failed resulted in animal death or severe thrombotic occlusion.  After two 
years, the valves were observed to induce severe intimal hyperplasia, which caused the 
valves to be functionless.  
 
In 1993, DeLaria et al studied bovine jugular vein valves as potential replacements for 
deep venous valves in humans [31].  They studied the performance of both fresh and 
gluteraldehyde-fixed vein valves with respect to reflux and opening pressure.  Fresh 
valves allowed a high leak-rate of 120 mL/min at an applied proximal pressure of 287 
mmHg, and fixed valves allowed a leak-rate of 40 mL/min at the same proximal pressure.  
The study reported that fixed valves opened at 1 mmHg, although the leaflets were fixed 
in the open position to begin with.   
 
Attempts at using cryopreserved human vein valves have also been pursued.  However, 
Neglen and Raju reported in 2003 that cryopreserved venous valve allografts resulted in 
“high morbidity, high occlusion rate, poor patency, and poor clinical results.”  They 
found nearly three-fourths of the cryopreserved valves required some transcommissural 
repair prior to implantation.  Thus, cryopreserved valves are not an effective option.   The 
poor performance of cryopreserved valves was attributed to the effects of 
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cryopreservation on structural integrity and the immunogenic response elicited after 
implantation [32]. 
 
Between 2001 and 2003, Pavcnik et al reported making a vein valve prosthesis for 
transcatheter delivery.  The valve comprised of nitinol wires and a sheath of porcine 
small intestine submucosa, an acellular material derived from porcine small intestines 
[33].  Twenty-five valves were implanted into sheep external jugular veins; 88% of the 
valves demonstrated good long term patency and competency [34].  The valves did show 
the ability to withstand 300 mmHg of backpressure, although leak-rate was not reported.  
However, these valves were tested against backpressure in a rigid tube; natural veins 
distend by 50% of diameter at high pressures, and it is more physiologically relevant to 
apply high proximal pressures in a vein-like environment.  The opening pressure gradient 
for the valve was 1 mmHg.  Valves that were placed incorrectly in the veins or tilted 
during deployment resulted in decreased function (12% of all valves), and 4% of all 
valves had thrombus formation [34, 35].  Curved veins and skewing had caused problems 
for the valve’s functionality.  While showing promise as a prosthetic vein valve, this 
valve may not be most appropriate for implantation into tortuous curvature of diseased 
veins.  Little has been reported on the valve’s durability and functionality after repeatedly 























Table 2:  Summary of current clinical therapies 
 
Clinical Therapy Purpose Disadvantages 
Anti-coagulation 
medication 
Prevent DVT Thins blood  
 
Bed rest, elevated feet Reduce pressure in 
lower leg 
Prevents active lifestyle 
Compressive hosiery Reduces pressure in 
lower leg 
Annoying for the patient 
Sclerotherapy  Cosmetic procedure 
to treat spider veins 
Useful only for superficial veins 
Vein stripping Removal of afflicted 
superficial veins 
Removes blood vessels 
Vein valve transplant Replace damaged 
deep vein valves 
Donor valves rarely available  






Table 3: Summary of prosthetic valve replacement studies in animals or humans 
 
Investigator(s) Valve type Outcome Failure mechanisms 
Hill, Schmidt et 
al (1985)  
Pellethane®  
(canine model) 
Occlusion of all 10 
valves after 8 days 
Poor patency 






Occlusion of all 10 
valves after 3 days; 
Valves opened at 4.5 
mmHg 
Poor patency 











No pressure testing 
Immunogenic 
response in humans; 
Opening pressure 
unknown 






40% valve implants 
resulted in thrombotic 
occlusion or animal 
death at 16 weeks 
Poor patency; 
Erosion of valve 
through vein 




(in vitro study) 
Opening pressure less 
than 10 mmHg; 
120 mL/min leak-rate 
for fresh valves; 
40 mL/min leak-rate 
for gluteraldehyde-
fixed valves 
Poor long term 
competency (leak-
rate is high); 
Immunogenic 
response in humans 
Pavcnik et al 
(2001-2003) 
SIS valve with 
nitinol 
(ovine model) 
88% long-term patency 
and competency. 
No data on cyclic life. 
Thrombus formation 
for valves in tortuous 
anatomy or tilted 
positions. 








“High morbidity, high 
occlusion rate, poor 
patency, and poor 
clinical results.” 








There are currently no commercially available prosthetic vein valves.  Work is continuing 
to address key problems of preventing thrombus formation and immunogenic response, 
evidenced by the progress by Pavcnik et al.  However, there remain many challenges, 
particularly in demonstrating cyclic life functionality in a vein-like environment.  Also, 
the prosthetic valves should be biocompatible and should not elicit an immunogenic 
response.  Thus, the material selected for the valve should be one that has demonstrated 
low thrombogenicity as well as low immunogenic response and is preferably in use in 
FDA-cleared medical devices.  Finally, unlike prosthetic heart valves, test methods have 
not been well-established for evaluating a prosthetic vein valve.  It is important for the 
research community to establish test methods for a venous valve, and to utilize design 






1) Define clinically relevant design requirements for a prosthetic vein valve 
The first goal of this research is to define a set of critical engineering design requirements 
that will serve as the driving factors in designing a prosthetic vein valve.  Little work has 
been done to methodically define comprehensive design requirements.  This research will 
use design methods to translate consumer needs into functional requirements, and create 
design criteria that a valve’s performance can be measured against.   
 
2) Develop relevant functional tests for assessing vein valve performance 
A second goal of this research is to develop tests that can be used to appropriately assess 
a vein valve’s functionality with respect to key design criteria.  There has been little work 
done to define functional testing of vein valves, and this research proposes methodologies 
for functional testing.  The tests will mimic human venous physiology, and will yield 
quantifiable and meaningful metrics that can be used to evaluate valve performance.   
 
3) Design and manufacture a clinically relevant functional prosthetic vein valve  
The primary goal of this research is to develop a novel prosthetic vein valve that can meet 
specified design requirements by undergoing functional testing.  Thus, concentration will 
be placed on creating a prosthetic valve that is biocompatible, hemocompatible, easy to 
manufacture, easy to implant, and has a reasonable and achievable path to FDA-
clearance.  The valve will be designed to maximize patient benefit and reduce patient 





Nearly 1 million new CVI patients arise each year in the United States alone.  About 40% 
of CVI patients have deep vein valve incompetence [36, 37].  Some medical centers have 
reported as high as 95% of patients that exhibited deep venous reflux having post-
thrombotic damaged valves [8].  It is these patients suffering from secondary 
incompetence that are the most likely candidates for valve replacement.  However, the 
small percentage of patients having primary incompetence in the deep veins could also be 
potential candidates for a prosthetic valve.  Thus, the potential consumer base for a 
prosthetic vein valve is about 400,000 CVI patients per year.  Assuming the prosthetic 
valve can be packaged into a stent-catheter delivery system for minimally invasive 
delivery, the total product price will be about $1000 dollars.  This pricing is based on 
existing vascular interventional products that utilize stent and catheter systems.  The 
multiplication of the price and potential patient population yields the estimated market 
size.  Thus, the estimated U.S. market size for this device is approximately $400 million 
per year.   
 
This is an untapped niche market; there is a distinct and urgent demand by vascular 
surgeons and patients for a medical device that can treat CVI effectively.  The market 




The majority of the patient population suffering from CVI is elderly.  However, people 
who spend much of their day standing and even some pregnant women are also 
susceptible to CVI.  Symptoms of incompetent deep vein valves include severe pain, 
infection, swelling, and ulcerations.  A descending venogram will discern the presence of 
primary or secondary incompetence.  The clinician can then determine if the benefit of 
implanting a prosthetic vein valve outweighs any potential risks associated with the 
surgery or device. 
 
The average patient has painful aches in the thigh or leg is often present, that recede only 
after the patient sits for 15 or 20 minutes.  Swelling begins after the patient gets out of 
bed in the morning.  Swelling continues to the point where shoes cannot be worn, and it 
becomes difficult to walk because of heaviness in the leg.  The quality of life is 
detrimentally affected – the patient cannot have an active lifestyle and is often instructed 
to remain in bed to prevent swelling.  A patient’s leg can have an unpleasant odor due to 
stasis dermatitis and ulcerations allowing bacteria to fester and rot the flesh.  It can be 
embarrassing for the patient to be in social situations when their legs smell. Thus, the 
patient not only suffers physically, but emotionally and mentally as well.  Patients are in 
great need of a clinical treatment that affords them improved health and quality of life.  A 




Currently, there are no prosthetic vein valves commercially available in the United States.  
Although this is a smaller market compared to coronary stents and Implantable 
Cardioverter Defibrillators, several companies are pursuing positions in the market.  
There are approximately twenty-five issued patents concerning prosthetic vein valves.  
Table 4 contains the U.S. patents that are displayed by the U.S. Patent and Trade Office’s 
(USPTO) website when using a simple search with keywords “vein valve” or “venous 
valve.”   
 
Table 4: Prior patents issued by USPTO involving vein valves 
 
U.S. Patent Number Inventor(s) Date of Issue 
4851001 Taheri. Jul., 1989 
4904254 / 5147389 Lane. Sep., 1992 
5358518 Camilli. Oct., 1994 
5500014 Quijano et al. Mar., 1996 
5607465 Camilli Mar., 1997 
5824061 Quijano et al. Oct., 1998 
6287334 Moll et al. Sep., 2001 
6299637 Shaolian et al. Oct., 2001 
6315793 Bokros et al. Nov., 2001  
6319281 Patel. Nov., 2001 
6494909 Greenhalgh. Dec., 2002 
6503272 Duerig et al. Jan., 2003 
6562069 Cai et al. May, 2003 
6585761 Taheri. Jul., 2003 
6602286 Strecker Aug, 2003 
6652578 Bailey et al. Nov. 2003 
6676698 McGuckin, Jr. et al. Jan., 2004 
6695878 McGuckin, Jr. et al. Feb., 2004 
6705585 Roy. Mar., 2004 
6716241 Wilder et al. Apr., 2004 
6752828 Thornton. Jun., 2004 





While there are various prosthetic vein valve designs that have been pursued in the past, 
many have shortcomings that prevent them from being sufficiently functional designs.  
Many valve designs contain rigid elements that can impose stress concentrations on the 
vein wall.   The following text describes the patented designs that are most similar to the 
invention presented in this thesis.  A comparison of these relevant patents to the invention 
of this research shows that this novel implantable prosthetic vein valve does not infringe 
on other patents.  
 
U.S. Patent 6,840,957, issued to DiMatteo et al on January 11, 2005 (“DiMatteo”) 
describes an implantable prosthetic valve comprising a radially self-expanding 
collapsible scaffold that supports collapsible leaf valves.  A radial expansion device, 
particularly one containing will place localized stresses on the vessel wall, potentially 
affecting the biological integrity of the vessel.  If the expanded scaffold diameter is 
anything less than the maximum distended vein diameter, the scaffold may lose retention.  
However, if the valve diameter is larger than the maximum vein diameter, during vein 
collapse at low pressures there will be high stress concentrations in the vein wall.  
Multiple cycles of collapse and distention can lead to vein wall fatigue and damage.   
 
DiMatteo et al also describes that the leaflets are formed with a metal framework, and the 
leaflets have a spring bias to either the open position or the closed position.  A spring bias 
towards the closed position could impede the valve opening at sufficiently low pressure 
gradients.  A spring bias towards the open position may not seal appropriately during 
reflux.  Also, the leaf valves are described to be in abutting edge-to-edge contact.  Line 
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contact sealing may pose risks in sealing appropriately when the valve exposed to a 
dynamic and tortuous anatomy, which is present in the venous system.  A more robust 
form of sealing in the venous system would entail a surface contact seal.   
 
US Patent 6,716,241, issued to Wilder et al on April 6, 2004, describes a valve with three 
parabolic lobes.  The valve has uniform elasticity and is fully flexible, making it easily 
deformable under muscular pressure and contractions.  However, a valve that deforms too 
easily may not be durable or robust in sealing.  Also, a valve with three lobes must 
contend with the elliptical cross-section of natural veins as well as muscular contractions. 
Muscle contracts may impose non-uniform stress and strain on the valve’s lobes, 
potentially causing them to fatigue at uneven rates.   
 
US Patent 6,494,909, issued to Greenhalgh on December 17, 2002, describes a radially 
expandable tube constructed of braided intermeshed filaments containing leaflets that are 
flexibly biased inwards.  Thus the leaflets are inhomogenously elastic.  Inwardly biased 
leaflets create additional resistance to antegrade flow.  In that situation, there is a risk that 
normal physiologic pressure gradients may not be able to open the valve, causing an 
obstruction of blood flow.   
 
Other references describe valves incorporating a rigid stent or support structure, such as 
the valve described by US Patent 6,562,069, issued to Cai, et al, on May 13, 2003.  The 
invention describes a valve for cardiac use which has an open orifice in its relaxed state, 
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and its leaflets are attached to a rigid commissural support system.  A valve that is open 
in its relaxed state may allow excess reflux. 
 
Various bio-prosthetic valves have been described by prior art (see US Patents 6,562,069 
and 5,500,014 as examples).  However, these inventions generally describe the fixation 
process of chemically treating autologous or heterologous venous valve vein segments.  
Fixation of such biological valves usually involves gluteraldehyde, an agent that 
crosslinks collagen, creating a generally stiffer valve.  Stiffer valves are not advantageous 
to have in the venous system, as they may not be sensitive enough to operate in low 






The primary consumers for a prosthetic vein valve are the end users: the patient and the 
surgeon and interventional radiologists who implant the device.  Additionally, secondary 
consumers are insurance companies which may include this device in its reimbursement 
options, as well as hospital buyers who will actually purchase the device directly for 
surgical use.  A manufacturing plant or manufacturing team can also be considered as 
having certain consumer needs of a product design, since the design greatly affects the 
quality and cost at which manufacturing will occur.  While hospital buyers and insurance 
companies have a financial stake in medical products, this thesis will assume that primary 
position of consumers belongs to those parties that most directly benefit from the design 
and manufacturing of the device.  Thus, emphasis will be placed on the needs of patients, 
surgeons, and manufacturing plants.  
 
Needs for major subsets of consumers are summarized in Table 5.  It is important to 
understand that some of these needs are not mutually exclusive from other needs.  For 
example, a medical device product can be made very cheaply at the hazard of reducing 
the quality of the product.  Thus, there is an optimization process that must take place to 
achieve certain benefits for some consumers without imposing additional risk to other 
consumers.  These consumer needs were described in broad terms, relevant to how each 
consumer would regard the prosthetic valve.  From these consumer needs, quantifiable 
functional requirements can be determined to specify what the product must deliver.   
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Table 5: List of key consumers and their respective needs 
 
 Patient Needs 
1 Resolved CVI, resulting in: 
     Decreased lower leg venous pressure  
     Relief of pain, swelling, ulcerations  
     Improved circulation  
     Minimized need for post-op anticoagulation and care 
2 Safe device 
3 Reduced cost of surgery, but not at the hazard of reduced quality 
4 Long life of device, beyond 10 years 
5 Reduced hospital time without reducing necessary care for patient  
6 Lower cost of operation without sacrificing options for procedures 
7 Minimized need for additional surgeries 
8 Reduced pain or discomfort from implanted device 
 Surgeon and Interventional Radiologist Needs 
1 Reduced risk of treatment using device compared to current treatments 
2 Increase in patient throughput without jeopardizing necessary time in 
hospital 
3 Wide range of device sizes to select from 
4 Standardized method for selection of size 
5 Sterile packaging and delivery 
6 Device that is tactile 
7 Diagrams and procedures for best practice of positioning, delivering, 
implanting 
8 Ability to deliver to site accurately and safely  
9 Device that can be viewed using imaging techniques (X-ray) 
10 Device that is forgiving to variations in implant technique 
11 Device that is designed to minimize human error  
 Insurance company needs 
1 Low cost to insurance companies 
2 Low risk of procedure to patient 
3 Demonstration of ability to support product 
4 Low occurrence of second surgery or repair 
 Hospital Buyer needs 
1 Cost-efficient product (overall costs of operation, product, and future 
patient care related to CVI are reduced) 
2 Demonstrated device safety and efficacy 
3 Demonstrated demand for device by patients and surgeons 
 Manufacturing needs 
1 Traceability in components and processes – design controls 
2 Ability to monitor product quality 
3 High yield rates 
4 Processes that are reproducible  
5 Low COGS (Cost of Goods Sold) 
 34
Table 5 (continued) 
 
6 Safe processes for operators 
7 Processes are easy to learn and train for, while maintaining accuracy and 
reliability 
8 Product that can be sterilized 





The critical functional requirements of a prosthetic valve were determined by translating 
the aforementioned consumer needs into engineering parameters that can be quantified 
and monitored.  A Quality Functional Deployment (QFD) chart was used to make this 
translation, and to identify key design parameters that will affect product performance 
(Figure 8).  The primary needs of patients, clinicians, insurance companies, hospital 
buyers, and manufacturing facilities were evaluated and described in three distinct 
categories of the QFD: 1) implantability, 2) functionality after implantation, and 3) 
manufacturing.  These three categories were chosen because they help define broad 
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Implantatability                                     
  Implantation causes minimal localized trauma •   •                     • • •     
  Implantation does not damage valve • • •           • • • •       •     
  Easy to manipulate during implantation • • • • • •                         
  Can be retracted or removed if necessary • • • • •                     •     
  Can be sutured easily • • •                         •   • 
  Can incorporate radiopaque tracers • • •                         •     
  Can incorporate hooks or barbs • • •                         •   
  Can incorporate a stent • • •                         •     
Functionality after implantation                                     
  Allows one-way flow (Patency)   •   • • • • • •     •   •   •     
  Prevents backflow of blood (Competency)       • • • • •   • • •   •   •     
  Is functional after 500,000 open-close cycles       • • • •   • •   • •     •     
  Low thrombogenicity                         • •         
  Maintains position (retention) •   •           •     •   •   •     
  Minimal leakage •     • • • • •   • • •   •   •     
  Causes minimal pain or discomfort •   •                         •     
  Performance unaffected by vein distortion • •   • • • •         •       •     
  Minimal stress concentrations on vein wall • • •             •   
  Resilient to tearing         • • • •   •   •         • • 
  Non-toxic                             •       
  Non-immunogenic                             •       
  Non-degradable                             •       
Manufacturing                                     
  Quality can be measured and assured • • • • • • • • • • •     •   • • • 
  Fast cycle time  • • • • • • • •               •     
  Manufacturing processes are robust • • • • • • • •               •     
  Low-cost tooling and machinery • • • • • • •             •   • •   
  Can be sterilized                             •       
  Homogeneity within material                               • • • 
  Scalable for vessel diameter • • • • • • • •               •     
  Proper surface finish                           •         
Design Specifications  A B C D E F G H I J L K M N O P Q R 
Critical Functionality Tests - - - - - - - - 1 2 2 3 4 - - - - - 
                   
 Test Type         
 1 Test for opening pressure         
 2 Test for reflux leakage         
 3 Test for cyclic life          
 4 Animal trial         
           
Figure 8: Quality Functional Deployment 
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The “implantability” category addresses requirements that concern primarily the surgeon, 
as well as the patient’s well-being during surgery.  Generally, a clinician wants to treat a 
larger number of patients in a more effective and efficient manner.  This can be 
accomplished by having an implantation procedure that is less complex, has reduced 
operation time, and poses less risk to the patient than the gold standard of valve 
transplantation.  Also a standardized method for device size selection should be 
developed to minimize complications that arise from incorrect selection.  Thus, specific 
consumer requirements include that the valve is implantable with the least invasive 
procedure possible, that it is easy to position and manipulate during surgery, and that it 
can be affixed in the vein via sutures, hooks, barbs, or a stent. 
 
The “functionality after implantation” category specifies requirements primarily for 
patients, but also address needs of surgeons, insurance companies, and hospital buyers.   
As described by Table 5, a patient receiving the prosthetic valve needs the valve to 
resolve their CVI, as well as be safe, economical, and have minimal risk for 
complications or need for additional corrective surgery.  These needs can be specified 
into consumer requirements.  For example, for a valve to resolve CVI, it needs to be 
patent, competent, last for a pre-described period of time, have low thrombogenecity, and 
maintain its position in the vein.  Meeting these and other requirements in the 
“functionality after implantation” will improve the valve’s ability to resolve CVI, and 
will help improve cost, safety, and reduce risk factors leading to complications.  This not 
only benefits the patient directly, but also the other consumers.  Improved cost, efficacy, 
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and safety positively address the needs of surgeons, insurance companies, and hospital 
buyers.   
 
Manufacturing was defined as the third main category to help specify consumer needs 
into consumer requirements.  Any product design must be created with manufacturing in 
mind to reap maximum benefits in both technical and financial performance of a product. 
It is important to note that this category not only brings to light manufacturing needs, but 
also directly relates to costs that trickle down and affect patients, surgeons, insurance 
companies, and buyers’ needs.  Addressing these needs early during the design phase will 




A QFD chart links consumer requirements to specific engineering parameters that can be 
measured and quantified.  This linking of requirements to engineering parameters helps 
ensure that design controls can be placed on the parameters to achieve and surpass key 
consumer requirements.  Three main types of engineering parameters were identified: 1) 
design parameters, 2) operational parameters, and 3) material parameters.  Design 
parameters were inclusive of geometric information that defined the physical shape and 
size of the device.  Operational parameters included performance attributes of the valve 
that could be assessed with testing; these operational parameters that became the bulk of 
this research.  Material parameters involved quantifiable aspects of the valve material.  
While these parameters are very important to the design of any medical device, for this 
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particular device they are governed primarily by the initial material selection.  
Accordingly, after the initial material selection, less emphasis was placed on the material 
parameters, and more emphasis was placed in addressing the design and operational 
needs 
 
Linking Requirements to Parameters 
After consumer requirements were specified and engineering parameters were identified, 
each parameter was examined to assess which requirements it addressed in the QFD, and 
the link was denoted with a dot mark.  In a commercial product development cycle, many 
tests are used to evaluate and verify a product’s engineering parameters.  However, due to 
time and resource limitation, this research concentrated on evaluating the valve’s 
functionality based on the most critical engineering parameters.  The primary objective of 
this research was to create a prosthetic vein valve that demonstrates functionality for 
eventual clinical use.  Thus, emphasis was placed on evaluating operational parameters, 
simply for the fact that these parameters were directly related to the functionality of the 
device after implantation.  Design features such as leaflet thickness, curvature, and 
contact length also play a role in the functionality of the device.  However, rather than 
creating tests that evaluate geometric features, tests were created to evaluate operational 
parameters.  This created a more clinically relevant evaluation of device functionality.   
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Critical Engineering Parameters 
Five parameters (four operational parameters and one material parameter) were 
designated as critical in producing a functional vein valve.  From an operational 
standpoint, opening pressure, proximal static pressure, cyclic life functionality, and valve 
leakage were all parameters that could be measured to quantify product performance.  
These parameters, above all other engineering parameters, defined the valve’s 
functionality in the most critical manner.  These are testable parameters with in vitro 
bench studies, and test results will characterize the valve’s functional performance.   
 
The most critical material parameter for designing a prosthetic vein valve is 
thrombogenecity.  Thrombogenecity of a material is its property of eliciting thrombus 
formation on its surface.  Thrombus formation, as described previously, is a major cause 
of prosthetic valve failure and often leads to obstruction.  With almost all medical 
devices, low thrombogenecity is a material parameter that is desired.  Thrombogencity 
can be measured by performing histological analysis of a surface area after the material 
has been exposed to blood with in vivo animal testing.  While this thesis identifies 
thrombogenecity as a critical engineering parameter, it is beyond the scope of the thesis 
to create a test for it.  However, a pre-clinical animal trial has been planned, and will be 
conducted within the coming months to assess the thrombogenecity and patency of the 





Three critical design specifications were imposed on the valve, including that the device 
1) withstand 300 mmHg of backpressure with less than 1.0 mL/min of leakage, 2) open 
with distal pressure gradients less than 5 mmHg, and 3) withstand 500,000 cycles of 
opening and closing while meeting or exceeding design criteria 1 and 2.  These critical 
design specifications stem from design specifications I, J, K, and L from Table 6 below.  
Table 6 depicts design specifications for each of the engineering parameters that were 
identified in the QFD chart (Figure 8).  The reasoning used for developing these 
specifications can be found in the section titled “Justification of Design Specifications,” 




Table 6: Engineering parameters and relevant design specifications 
 
Item Design Parameter Design Specification 
A Outer diameter The largest outer diameter (OD) should not be 
greater than 1.2 times the diameter of the vein.   
B Inner diameter The area of the valve’s lumen should not be less 
than 90% of the area of the vein’s lumen.   
C Length of valve A length between 1.5 and 2.5 times the OD of the 
valve is desirable.  
D Leaflet length The leaflet length should range between 1 and 2 
times the diameter of the vein.      
E Leaflet thickness Each leaflet thickness should be less than 5% of the 
valve diameter.   
F Leaflet curvature The leaflet curvature could range between being 
flat panels to have a radius equivalent to half of the 
valve diameter.    
G Leaflet contact length Sealing contact length should range between 20 and 
50 percent of the diameter of the valve.   
H Orifice area The open position the orifice area should be greater 
than 30% percent of the cross-sectional area of the 
vein. 
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Table 6 (continued) 
 
Item Operational Parameter Design Specification 
I Opening pressure The pressure gradient required to open the valve 
and cause forward fluid flow must be less than 5 
mmHg. 
J Proximal static pressure Valve must structurally bear at least 300 mmHg of 
static pressure and must comply with valve leakage 
specifications 
K Valve leakage The valve must not leak more than 1.0 mL of fluid 
per minute at any proximal pressure level 
maintained for a period of 30 seconds. 
L Cyclic life functionality The valve must open and close in simulated 
physiologic conditions at least 500,000 cycles, and 
meet design specifications I, J, and K.  
Item Material Parameter Design Specification 
M Thrombogenicity The valve and material must not promote 
significant thrombus formation over a period of 
three months in an animal trial.   
N Surface roughness No current specification. 
O Material composition The valve must not bio-degrade when implanted in 
the human body.    
P Material stiffness Material stiffness less than 1 GPa is desirable. 
Q Porosity Material porosity uncommon to polymeric 
chemical structure, such as holes, bubbles, or voids, 
must not be present.   
R Suture retention strength A single 6-0 prolene suture should have a pull-out 
strength of at least 2.4 Newtons when subjected to 




Justification of Design Specifications 
A. Outer diameter - For the scope of this thesis, the valves were designed for 
implantation into a human adult Common Femoral Vein (CFV), which has an 
average diameter of about 12 mm [38].  For purposes of testing valves using 
standard tubing and fittings, it was more practical to design valves for a 10 mm 
inner diameter vein, and thus prosthetic valves were sized according.   
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B. Inner diameter – The lumen of the valve be as large as possible for decreased 
flow resistance.  However, another important requirement is that the thickness of 
the valve is sufficient for implantation and fixation.  A reasonable compromise 
between the two requirements is that the area of the valve’s lumen should not be 
less than 90% of the area of the vein’s lumen.   
C. Length of valve – A length between 1.5 and 2.5 times the OD of the valve is 
desirable.  The length should be short enough that the valve does not interfere 
with the hemodynamics of branch flow near the valve site, yet long enough to 
provide longitudinal stability. 
D. Leaflet length – In a natural bi-leaflet vein valve, the leaflet length is usually 
twice the diameter of the vein [39].  A prosthetic vein valve’s leaflets can 
probably be shorter and still function.  The leaflet length should range between 1 
and 2 times the diameter of the vein.      
E. Leaflet thickness – Natural vein valves have leaflet thicknesses ranging between 
20 and 50 microns, and derive their strength from collagen in the leaflet [14].  The 
leaflets of a prosthetic valve can be made that thin; however the strength of the 
leaflets may not suffice for valve functionality.  Generally, the leaflets should be 
made as thin as possible without sacrificing competency and cyclic life 
functionally.  As a reasonable specification, the each leaflet thickness should be 
less than 5% of the valve diameter.   
F. Leaflet curvature – Natural vein valves have a parabolic shape, enabling 
antegrade flow at low opening pressures and competency at high proximal 
pressure.  A prosthetic vein valve could mimic this anatomy to enhance its 
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functionality.  The leaflet curvature could range between being flat panels to have 
a radius equivalent to half of the valve diameter.    
G. Sealing contact length –The sealing contact length is the axial distance that the 
leaflets coapt to form a sealing surface.  This length should be sufficient to 
prevent leakage; in situ cusp contact length is generally 1/5 to ½ the inner 
diameter of the vein [40].  This indicates that a prosthetic bi-leaflet valve’s sealing 
contact length should range between 2 and 5 mm for a prosthetic having a 10 mm 
OD.   
H. Orifice area – B-flow ultrasound scanning techniques by Lurie et al revealed that 
the cross-sectional orifice of an open valve is about 35% of the area of the vein 
cross-section distal to the valve [15].  Thus, a prosthetic valve should have similar 
or better orifice area, and therefore should be greater than 30% of the normal vein 
cross-sectional area.  Also, it is important to note that a natural valve’s orifice is 
elliptical in nature.  The major axis of the ellipse is the inner diameter of the vein 
and the minor axis is the distance between the two cusps.    
I. Opening pressure – Human vein valves are typically open when a human is at 
rest in the standing or sitting position.  Blood flow during these situations is 
driven not by the calf pump, but by vis a tergo flow from the suction of the right 
atrium of the heart.  The pressure gradient driving this venous flow is quite low, 
and native vein valves typically open with less than a 5 mmHg pressure gradient.  
Thus, a prosthetic vein valve must be designed to open with the same pressure 
gradients.   
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J. Proximal static pressure – Normal physiologic static pressure imposed 
proximally on the valves of the CFV range between 35 mmHg to about 50 
mmHg.  This is the result of the hydrostatic pressure column of blood from the 
right atrium of the heart to the most proximal valve [16, 17].  During the valsalva 
maneuver, pressure in the veins of the upper leg can increase to nearly 100 mmHg 
[41].  The valsalva maneuver occurs when the glottis is closed. This includes 
actions in everyday activity, such as lifting a heavy object, having a bowel 
movement, or exercising.  Venous static pressure near the foot is normally 
between 90 and 100 mmHg [42].  While this prosthetic valve was initially 
designed for implantation into the common femoral vein, it is certainly scalable 
for other vein sizes and locations.  Also, there may be a real need to implant 
several valves spaced throughout the leg veins to combat the more severe cases of 
CVI, and thus a prosthetic valve should withstand the venous environment of the 
lower leg veins as well.  Thus, while 100 mmHg is the average maximum static 
venous pressure, it can be estimated in worst-case scenarios that maximum 
venous pressure could be 150 mmHg.  Applying a safety factor of 2 then results in 
design specification J: the valve must functionally and structurally withstand 300 
mmHg of proximal pressure. 
K. Valve leakage –  Valve leakage can only occur when there is a positive pressure 
gradient applied from the proximal side of the valve.  During rest in either a 
standing or sitting position, the prosthetic vein valve will be open, and the valve 
will not leak in the retrograde direction during this time.  However, reflux could 
occur during a sudden change in posture from sitting to standing, or during 
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muscle movements such as calf pumping.  The calf pumps approximately 10 to 20 
mL of blood through the deep leg veins with each muscle constriction [9].  It is 
reasonable to consider a valve functional even if it allows leakage less than 10% 
of blood volume flowing in the antegrade direction per calf pump.  Of the lower 
limit of 10 mL per stroke, 10% imposes a leakage condition of 1.0 mL of blood.  
It is important to normalize this per time; a metric that can be used to assess the 
competency of a vein valve is its leak-rate (volume of leakage per minute).  
L. Cyclic life functionality – Any implanted medical device must have reasonable 
longevity and remain functional throughout its intended life.  There are certain 
“rules of thumb” that medical device companies use for specifying intended life 
of their products.  For artificial heart valves, companies design their products to 
withstand “10 years, 40 million cycles” as a target life expectation, based on the 
number of heart beats in the average human.  Prosthetic vein valve life can also be 
assessed in a similar manner.  The dynamics of the valve opening and closing 
during calf pumping action cause the most relevant forces on and displacement of 
the valve structure.  These forces and displacements cyclically fatigue the valve, 
especially the leaflets.  The calf pumps about 40 times a minute (0.67 Hz) during 
normal walking cadence [8, 9].  This research assumes that an elderly patient 
would have such a brisk walking cadence, and is actively walking a total of about 
1 hour a day.  This means that in an average day, the valves will open and close 
about 2400 times.  In one year, the valve will open about 876,000 times.  Thus, if 
the valve is to last 10 years, it should be able to cycle nearly 9 million times and 
still remain functional.  Cyclic performance depends on two main factors: good 
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design, and good manufacturing.  It is a reality that a valve fabricated in a lab 
environment without statistically controlled manufacturing processes will not 
meet this design criterion.  Such performance demands precision manufacturing 
that expensive machinery, tooling, and quality control can provide.  However, if a 
lab-fabricated valve can achieve even 5% of this cyclic life criterion, it will have 
demonstrated concept feasibility of the design.  Thus, the design criterion for a 
lab-fabricated valve is to remain functional after 500,000 cycles of opening and 
closing. 
M. Thrombogenicity - Thrombus formation should be kept to an absolute minimum. 
The best method for evaluating thrombus formation is to implant the valve into 
the venous system of an appropriate animal model.  Animal models that could be 
appropriate include canine, porcine, and ovine models.  Histological analysis 
using Carstairs stain can quantify thrombus formation.  The valve should elicit 
thrombus formation that is less than or equivalent to the amount caused by current 
vascular graft products containing Dacron® or ePTFE. 
N. Surface roughness – In general, the lower the surface roughness, the less impact 
the surface will have on thrombogenesis.   
O. Chemical composition: No specification or limitation.  It is, however, strongly 
recommended that materials known to have chemical compositions that are stable, 
biocompatible, non-toxic, and non-immunogenic be used for the device.  It is 
highly recommended that the material used for a vein valve is a material that has 
been used in FDA-cleared medical devices. 
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P. Material stiffness – There is no defined elastic modulus that the valve material 
should have.  However, one guideline to use suggests that the material stiffness 
should be similar to that of native vein and vein valves, or less than 1 GPa.  Also, 
the prosthetic valve material should have a breaking strength equivalent to or 
greater than native valves, which is between 8 and 10 MPa [43].  Material 
stiffness is a very important parameter because it impacts the severity of stress 
concentrations that are imposed on the vein wall.  Low material stiffness will 
impose less stress concentrations and less trauma by radial force than high 
material stiffness. 
Q. Porosity – No current specification.  Porosity specifications can vary depending 
on the material the valve is comprised of, and what the constituents are in the 
event composites are used.  For example, if Dacron ® is incorporated into the 
valve, porosity will be present due to the inherent nature of the mesh.  Porosity 
may be advantageous in some situations, because it promotes neointimal growth 
and could facilitate circumferential sealing of a valve having a central orifice.  
However, unwanted porosity can reduce cyclic life significantly, and will 
adversely affect the valve’s structurally integrity.  Thus, as a general guideline, 
material porosity uncommon to specific polymeric chemical structures, such as 
holes, bubbles, or voids, must not be present.   
R. Suture retention:  The Association for the Advancement of Medical 
Instrumentation (AAMI) has developed a protocol for suture retention in vascular 
grafts, outlined in AAMI VP20-1994, Section 5.8.  A conservative engineering 
analysis was used also to determine the desired suture retention strength.  
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Equations 1 and 2 were used to calculate the desired suture retention strength.  
Table 7 describes the parameters used in the calculation.   
 
Table 7: Description of variables and values used to calculate suture retention  
strength  
 
Variable Description Value 
Fsuture Suture retention strength Unknown 
Fmax,proximal Maximum proximal force imposed on valve Unknown 
Pproximal Maximum proximal pressure 40,000 Pascals 
(300 mmHg) 
Across-section Cross-sectional area of 10 mm diameter 
valve  
0.0000785 m2 
SF Desired safety factor 3 
n Number of interrupted sutures desired on a 















Equation 2: Maximum proximally applied net force on valve in femoral vein 
 
 
max, secproximal proximal cross tionF P A −=  
 
 
Thus, the desired suture retention strength of the valve using 6-0 Prolene sutures 
is 2.4 N.  For future development of the valve, this can be tested using the AAMI 
VP20-1994 protocol for Cardiovascular Implants – Vascular Prosthesis.  For 
comparison, the AAMI protocol for 6-0 Prolene suture material showed suture 
retention strength for porcine carotid arteries to be 7.2 ± 3.1 N [44].  In 1999, 
Niklason reported a tissue-engineered vascular graft having a suture retention 
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strength of 0.9 N [45].  Thus, a design specification of 2.4 N as the suture 
retention strength is of the same order to biologic vessels and prosthetic vascular 
grafts, and is a reasonable specification.   
 
Final Relevant Design Specifications for Functional Testing 
Table 8 lists the final clinically relevant design specifications for the scope of this thesis.  
These final specifications stem largely from the operational specifications, and were 
defined in terms of three important clinical parameters: patency, competency, and cyclic 
life functionality. Low thrombogenecity is another key design specification that a 
clinically functional valve must meet.  However, it is beyond the scope of this thesis to 
test for thrombogenecity. Thus, all subsequent tests and results are based on 
demonstrating valve functionality for the first three key clinical parameters.   Also, while 
the remaining design specifications in Table 6 are all important, the final design 
specifications were chosen because functionality can be easily traced and assessed for 
these specifications. 
 




Parameter Design Specification 
1 Patency The pressure gradient required to open the valve 
and cause forward fluid flow must be less than 5 
mmHg. 
2 Competency Valve must structurally bear at least 300 mmHg of 
static pressure and must not leak more than 1.0 
mL/minute for all tested pressure from 0 to 300 
mmHg. 
3 Cyclic life 
functionality 
The valve must open and close in simulated 
physiologic conditions for at least 500,000 cycles, 
and continue to meet design specifications 1 and 2 
at all test intervals.   
 51




Parameter Design Specification 
4 Low 
thrombogencity 
The valve must elicit less thrombogenesis in a three 
month span in an animal trial than common 
vascular graft materials such as Dacron® and 
ePTFE.  Tests will not be conducted for this design 




The device and all configurations are to be used only to treat CVI patients who have 
symptoms of severe pain, leg swelling, and ulcerations, and confirmed primary or 
secondary venous valvular incompetence.  This device is indicated for use in leg veins, 
and should be implanted at a site distal to the iliac vein, below the inguinal canal.  The 
device is for use in veins having diameter greater than 3 mm.  The device should be 
implanted in a location where the vein wall is structurally intact.  Only a clinician trained 
in treating CVI should prescribe this product.   
 
Contraindications  
This device is not indicated for use in patients exhibiting phlebitis, infection, or cancer in 
the legs.  The device should not be used in patients who have existing cardiac pathologies 
that limit cardiac output.  The device is not indicated for use in patients who may be at 
adverse risk during implantation surgery.  The device should not be implanted into veins 
having diameters less than 3 mm.  The device should not be implanted at the same site a 
damaged native valve exists; the damaged native valve should be removed in a 







While there are various materials that are researched for biomedical use, there is quite a 
limited selection of materials that are presently used in medical devices cleared by the 
FDA (Food and Drug Administration).  The primary objective of this research was to 
create a functional prosthetic vein valve for eventual clinical use.  This implies that if the 
technology is to reach patients, it must be commercializable and also achieve FDA 
clearance.  Thus, material selection was based on existing materials that have been used 
in medical devices sold in the U. S.  It is important to note that the FDA does not clear or 
approve specific materials for clinical use; it only clears devices.  However, it is a good 
starting point to consider the materials used in FDA-cleared medical devices as potential 
candidates for use in a prosthetic vein valve. 
 
Commonly used materials in cardiovascular medical devices include 
polytetrafluoroethylene (PTFE), expanded- polytetrafluoroethylene (ePTFE), 
polyethylene teraphthalate (PET), and polyurethanes (PU).  Other materials include 
polyesters, hydrogels, silastics, collagens, elastins, Room Temperature Vulcanized (RTV) 
rubbers, and silicone.   
 
There are several critical design specifications that a material must meet or exceed to be 
considered for use in a prosthetic vein valve, described in detail earlier in Table 6.  The 
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material must have low thrombogenecity, low surface reactivity, low surface roughness, 
must elicit low immunogenic response, and must maintain chemical and compositional 
stability during the intended functional life.  Additionally, the material cost should be 
low, and should be easy to manipulate into various shapes for the valve design.  Ideally, 
the valve should be flexible, and thus the material should have mechanical properties that 
are conducive to valve flexibility.  Also, the material must be able to incorporate sutures, 
stents, or other thin metal hooks or barbs without tearing or degrading.  Available 
materials were assessed based on these requirements.   
 
A material called poly(vinyl-alcohol) cryogel (U.S. Patent 5,981,826), was used 
throughout this research as the material of choice [46].  Poly(vinyl alcohol) (PVA) 
cryogel is a material within the class of hydrogels.  Hydrogels have the unique property 
of being hydrophilic, meaning they are compatible with an aqueous environment such as 
the human body.  Hydrogels can be created to have a wide range of stiffness and are easy 
to mold and shape.  A hydrogel generally needs to have its chemical and physical 
composition stabilized via cross-linking.  Cross-linking can be achieved by chemical 
fixation, however this process often renders the hydrogel less biocompatible.  Another 
method of cross-linking is via a sequence of freezing and thawing the hydrogel.  With 
each successive freeze-thaw cycle, a hydrogel increases its bulk stiffness.  This method 
prevents non-biocompatible chemicals from entering the hydrogel.   
 
PVA has been shown to have very low thrombogenecity [47, 48].  Additionally, it is 
biocompatible and is being used in FDA-cleared medical devices.  PVA is easy to 
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manufacture, and can be poured or injected into molds for creating a product.  It can be 
made to be highly elastic or extremely stiff by varying the material composition or 
processing techniques.  Cross-linking PVA with freeze-thaw cycles, and thereby creating 
the cryogel, affords the material greater biocompatibility than chemical fixation.   
 
PTFE and ePTFE materials, such as Gore-Tex ®, are relatively stiffer materials, and 
while useful for vascular grafts, may be too stiff for use in a vein valve, an application 
where a more elastic material would be advantageous.  Generally PTFE and ePTFE 
should be created in the shape of the desired medical device; vascular grafts are often 
manufacturing using an extrusion process.  Valve geometry is more complex than tubular 
geometry, and manufacturing a valve of PTFE and ePTFE could be an expensive process.   
 
PET materials, such as Dacron® (DuPont), are used often as a vascular graft material.  
These grafts use woven PET fibers to create a porous mesh that promotes intimal growth 
of the surrounding vasculature, as well as some thrombus formation.  While this material 
and composition work well for a graft, it will be complicated to fabricate into the shape 
of a valve.  Also, PET elicits thrombus formation, something that should be minimized in 
a venous environment.   
 
Various rubbers, silastics, and silicone materials are advantageous for valve material 
because of their elasticity.  Different chemical compositions and manufacturing processes 
can vary the stiffness of these materials, and thus the flexibility of the valve can be 
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adjusted as needed.  However, these materials also tend to be brittle in nature, a 
characteristic that is a disadvantage for a valve.   
 
Biologic materials such as collagens and elastins as well as small intestinal submucosa 
(SIS), are good materials for creating a valve that has similar mechanical properties to a 
natural valve.  Natural valve leaflets are comprised of collagen fibers, and the valve 
derives much of its strength from the arrangement of these fibers.  However, collagen and 
elastin must be obtained from a biologic source: either a human donor or an animal 
donor.  SIS is typically derived from pigs.  Tissue, collagen, and elastin can be 
chemically treated or cryopreserved to fix the mechanical properties and prevent 
degradation.  It is generally known that gluteraldehyde, while an effective fixation agent, 
can cause carcinogenic and immunogenic responses from tissue surrounding the 
implanted device.  Also, gluteraldyahyde tends to increase the stiffness of the tissue it is 
fixing, which could increase the pressure gradient required to open the valve.  
Additionally, studies have shown that cryopreserved vein valves elicit an immunogenic 
response, and the structural integrity of the valves was affected by the freezing and 
thawing process [32].  Tissue, collagen, and elastin processing is complex; quality control 
of such a prosthetic valve is not an easy matter, when compared to a valve involving 
more traditional manufacturing techniques.  Thus, because of complications that can arise 
from chemical fixation and cryopreservation, bioprosthetic valve designs were not 






Concept 1: Bileaflet Valve – Pre-open commissure 
The first concept design for a prosthetic vein valve involved a bileaflet valve with its 
leaflets positioned slightly open.  Pre-opened leaflets afford the advantage of ensuring 
valve patency.  This can be beneficial in the leg veins during rest, where the pressure 
gradient driving blood flow back to the heart is typically less than 5 mmHg.  However, 
during reflux, the open leaflet configuration must still close sufficiently to achieve 
competency and maintain leakage below 1.0 mL/min.   
 
This valve prototype, along with prototypes for Concept 2 and 3, was created by injecting 
PVA into a silicone two-part mold.  A complete description of how silicone molds were 
made can be found in the section titled “Valve fabrication.”  The valve dies for making 
the molds were created by hand using clay, and carefully sculpted into their final shape 
with needle-point forceps and surgical scissors.  The clay was baked at 130 °C for about 
30 minutes.  The hardened clay valve dies were finished and polished with jeweler’s files.  
This positive die was then used to create a two-part silicone cavity mold for creating 
valves of PVA.  The same methodology for creating two-part silicone molds was used for 









The distinguishing feature of this valve design is that the leaflets are positioned to create 
a slightly pre-opened commissure.  This design was created with the hypothesis that a 
pre-opened commissure would facilitate patency, while physiologic proximal pressure 
would be sufficient to cause the leaflets to coapt and seal.  Each leaflet arcs towards the 
lumen of the valve, meeting at the middle.  During reflux, the valve’s leaflets should 
deform under proximal pressure and touch to create a sealing plane.  This plane is a 
critical feature of the prosthetic valve; a plane of contact provides more sealing surface 
than just a line of contact sealing.  In a tortuous and dynamic venous environment, 
leaflets creating line contact may not seal as effectively as leaflets creating planar contact.   
 
Concept 1 testing:   
A prosthetic valve of Design Concept 1 was created by injecting 15% PVA into a two-
part silicone mold.  The valve underwent 3 freeze-thaw cycles, with a freezing time of 12 
hours and a thawing time of approximately 3 hours.   
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The valve was placed in a clear plastic tube having a 10 mm inner diameter. The valve 
was then exposed to a 100 cm column of water, thus imposing a pressure of 100 cmH20 
(approximately 74 mmHg) on the valve leaflets.  However, it became immediately clear 
that this valve design did not seal against reflux.  The pre-opened leaflets simply did not 
coapt like they were intended to.  The leak-rate was approximately 1 mL per second, 
much higher than the design criteria of 1 mL per minute.  Based on this failure of 
competency, the idea of a valve manufacture of PVA with pre-opened leaflets was 
discounted.  A flexible valve having leaflets that are not pre-opened could seal more 
effectively against reflux.   
 
Concept 2: Bileaflet Valve – Pre-closed Commissure 
The structure of this valve is essentially the same as Design Concept 1.  However, in this 
case, the leaflets are not pre-opened, but rather are sealing in their natural state.  When 
the valve is free from any externally applied forces, the leaflets contact each other 
without exerting force on each other.  This absence of a spring bias in the leaflets ensures 
that resistance to antegrade flow is minimized, a desirable attribute of a valve design.  A 
valve closed in its relaxed state may prevent leakage of blood during retrograde flow 
better than a valve that is open in its relaxed state.  This valve prototype was also created 
by using clay to make a two-part silicone mold (Figure 10), and then injecting PVA into 
the cavity mold (Figure 11).   
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Figure 11:  Design concept 2.  PVA valves are made in silicone mold via injection 
molding (left).   One PVA valve is removed and compared to clay die (right).  The PVA 
valve had dried for about 30 minutes; hence it shrank slightly in size. 
 
 
Concept 2: Initial testing 
A 10 mm diameter valve was placed in a 10 mm ID flexible tube composed of Salubria® 
biomaterial (Salumedica, LLC, Atlanta GA) for initial evaluation of leakage during 
reflux.  The valve was placed such that a plastic fitting abutted to the distal end of the 
valve to prevent valve migration.  The tube with valve was tied onto another plastic 
fitting connected to a hand-operated syringe pump, with a pressure transducer measuring 
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proximal hydrostatic pressure.  At a pressure above 20 mmHg, leakage occurred 
profusely around the circumference of the valve.  Because this did not appropriately 
evaluate the valve, testing was stopped, and a redesign of the valve was initiated.   
 
Concept 2: Redesigned with flared edges for sealing 
A flared inlet and outlet were added to the bileaflet valve to help seal against 
circumferential leakage.  The concept of a flared inlet or outlet is multi-purposeful.  It 
facilitates circumferential sealing of the valve against the intimal layer of the vein wall.  
Circumferential sealing is paramount in preventing leakage during retrograde flow, and 
the flared inlet and outlet ensure that a good seal is created.  The flared inlet and outlet 
may help alleviate stress concentrations in the vein wall during distension.  In essence, 
the inlet and outlet were designed to help smoothly transition the vein wall from a 
diameter equivalent to the vein valve to the vein’s distended diameter, minimizing 
damage to the vessel wall.  This will be particularly helpful if the remaining sinus region 
of the affected vein is intact, and needs to distend in its natural manner. 
 
      
 






Figure 13: Clay valves for positive die for fabricating re-designed concept 2.  Note the 





Figure 14:  Positive dies and negative two-part silicone molds formed around the clay 
dies.  The mold bottom is on the left, the mold top is on the right. 
 
 
Redesigned concept 2 testing:  
The redesigned bi-leaflet valve demonstrated competency at physiologic proximal 
pressures (35 to 50 mmHg), and opened at a pressure of 5.9 ± 0.9 mmHg when placed in 
the Salubria® tube.  Figure 15 depicts the valve’s leak-rate performance for proximal 
pressures ranging from 0 mmHg to over 300 mmHg.  At pressures below 230 mmHg, the 
valve met the design criteria of having a leak-rate less than 1.0 mL/min.  The valve’s 
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opening pressure did not meet the opening pressure design criteria of less than 5 mmHg. 
However, the opening pressure is reasonably close, and demonstrates the concept’s 
potential to meet the design requirements.  With minor improvements in design, material, 
and manufacturing, this valve concept was deemed to have potential for functionality 
even at 300 mmHg.   
 





























Figure 15: Design Concept 2 meets proximal pressure criteria at physiologic venous 
pressures, and shows promise to be functional at higher pressures 
 
 
Design Concept 3: Parabolic valve 
This valve design is unique in that it allows forward flow around the circumference of the 
valve, rather than through a central orifice as most conventional valves do.  The design 
intent of this concept was to help negate concerns of circumferential leakage.  Thus, 
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rather than trying to prevent circumferential leakage, the valve utilizes the circumference 
as the flow path during antegrade flow, with the periphery of the paraboloid seal against 
the vein wall during reflux. 
 
 
      
 




      
 




                   
 
Figure 18: Parabolic valve dies being extracted from mold (left).  PVA valve being 
extracted from mold (right) 
 
 
      
 
Figure 19: Side view (left) and distal view (right) of parabolic valve clay dies compared 
to PVA valves.  The valves had dried for 30 minutes, hence the slight shrinking in size. 
 
 
The valve was designed to be anchored to the vein via three fins that extend distally from 
the paraboloid.  Anchoring could be achieved by suturing the fins into place, with 
transmural interrupted sutures.  Another mode of fixation could incorporate a balloon-
expandable or self-expanding stent into the distal half of the valve.  For purposes of 
concept testing, anchoring was not pursued.  Instead, fixation was achieved using 
retention rings.  
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Concept 3 testing: 
The parabolic valve allowed a leak-rate greater than 1.0 mL/min at proximal pressures 
greater than 50 mmHg (Figure 20).  The opening pressure for the parabolic valve was 
26.4 ± 4.6 mmHg, far greater than the design criteria of 5 mmHg.  The fins were prone to 
failure; one of the fins cracked and buckled at a pressure of about 150 mmHg.   
Based on the poor performance of this concept, a parabolic, circumferential flow valve 
was not considered a very good option for a prosthetic vein valve.   
 




























Design Concept 4: Ball and Cage Valve 
Ball and cage valve designs have traditionally been used as cardiac valve replacements 
(Figure 21).  It is reasonable to at least consider existing cardiovascular medical devices 
for use as a prosthetic vein valve.  However, there are several disadvantages that prevent 
a ball and cage valve from being a contending design as a vein valve.  First, veins are 
thin, flexible, collapsible tubes, and placing a bulky, rigid object like a ball and cage 
valve can erode through the vein walls.  Secondly, ball and cage valve operation is driven 
primarily by bulk fluid flow, not fluid pressure.  This valve type requires high blood flow 
conditions to move the ball and open the valve.  There is neither high velocity nor high 
blood flow conditions in the venous system of legs, and implanting a ball and cage valve 
in that environment would be a poor decision.   
 
 
         
 




         
 




Design Concept 5:  Mechanical Leaflet Valve 
Mechanical leaflet heart valves can be considered as an option for venous valve 
replacement, albeit they are probably the last option for the venous environment.  Failure 
of prior attempts at using mechanical heart valves is evidence enough that a metal valve 
will cause multiple problems of trauma, inflammation, thrombosis, and intimal growth 
[30].  While mechanical valves are suitable as heart valve replacements, the flow and 
pressure conditions of the heart vastly differ from leg veins, and more suitable vein valve 
prosthetic designs should be examined.  Thus, mechanical leaflet valves were not 
considered as a feasible option for this research.      
 
          
 





Design Concepts and Implantation Modes 
Throughout this research, emphasis was placed on creating a functioning valve that could 
be tested in vitro.  In vivo work, particularly implantation technique, is a vital part of any 
product development phase for a medical device.  However, implantation using standard 
stenting and catherization necessitates incorporation of commercially available vascular 
interventional products.  Until recently, the valve in this research had not reached 
development maturity for the incorporation of commercial products to be a practical 
prospect.  It was impractical to test the valve’s implantability during the scope of this 
research; testing the valve’s functional performance was a greater priority.  Thus, this 
research does not include any test results or concentrated design efforts on 
catheterization, stenting, or the use of hooked or barbed protrusions.  Nevertheless, valve 
concepts were designed to be conducive to various implantation techniques.  The 
discussion section (Chapter 4) will discuss potential implantation techniques. 
 
Design Selection Process  
Five critical engineering parameters were selected as the metrics for analyzing Concepts 
1, 2, and 3 for potential functional performance.  Concepts 4 and 5 were abandoned since 
historical data did not support their use.  A Pugh Chart (Table 9) was used to summarize 
each design’s performance or potential for performance in relation to the most critical 
engineering parameters.  A plus sign (+1) denotes a case where a design has either 
demonstrated functionality or shown potential to demonstrate functionality with respect 
to an engineering parameter.  A minus sign (-1) denotes a case where the design failed to 
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be functional or failed to show promise of functionality.  A zero (0) denotes a case where 
the design’s performance is unknown based on lack of testing.  
 
 
Table 9: Pugh Chart used for design selection 
 
 Design Concept 






Opening pressure  
(less than 5 mmHg) +1 +1 -1 
Proximal static pressure 
(up to 300 mmHg while 
incurring no more than 1.0 
mL/minute leak-rate) 
-1 +1 -1 
Cyclic life functionality 
(maintain opening pressure, 
proximal static pressure, and 
valve leakage requirements 
even after 500,000 cycles 
0 0 -1 
Thrombogenecity 
(Significant thrombus 
formation is not desired) 
+1 +1 +1 
Total Score 1 3 -2 
 
 
Summary of concept testing and description of scoring 
A bi-leaflet valve with a pre-opened orifice allowed forward flow with less than a 5 
mmHg pressure gradient.  Concept testing showed that the bi-leaflet valve with a sealed 
orifice has promise of opening with a pressure gradient less than 5 mmHg.  Thus both 
concepts were assigned a +1 for the opening pressure parameter.  However, the parabolic 
valve needed an opening pressure above 20 mmHg, well above the design criteria, and 
thus the valve was assigned a -1 value for that parameter.   
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Of the three designs, concept testing showed that the bi-leaflet valve with closed leaflets 
was the only valve that demonstrated potential of withstanding 300 mmHg of 
backpressure and having a leak-rate less than 1.0 mL/minute.  Thus, it was the only 
design that was assigned a +1 value.   
 
It is difficult to assess cyclic life functionality based on only a few concept tests 
involving hydrostatic pressure.  Thus, the two bi-leaflet designs were assigned a score of 
0.  The parabolic valve design was assigned a score of -1, because in proximal static 
pressure testing, one of the fins cracked and buckled.  This highlighted the vulnerability 
of this particular design to high pressures.  The fins are design features that may not 
tolerate long-term cyclic pressurization, and may not meet the cyclic life functionality 
requirements. 
 
All valve concepts were assigned a +1 score for the thrombogenecity requirement.  This 
assignment is primarily based on the material of use. PVA is a material that has low 
thrombogenecity, and since all three designs will utilize PVA, all designs received a good 
score.  It is important to note that different valve geometries may affect the amount or 
speed at which potential thrombogenesis may occur.  However, the shape of the valve 




The final prosthetic valve design was modeled in Solidworks® v. 2004 CAD software 
(Solidworks Corporation, Concord, MA).  The valve was created with a single leaflet 
piece, with no orifice.  This allowed a post-molding cutting process to create the orifice 
to ensure that the leaflets coapted and sealed properly.  The valve body is shaped like a 
tube.  The inlet and the outlet of the tube are flared outwards to facilitate circumferential 
sealing (Figure 24).  Tube thickness decreases at the inlet and the outlet to minimize the 
profile of the valve in the vein and to allow the valve ends to conform easier to tortuous 
venous anatomy.  All edges of the valve are smoothened with rounds or surface fillets.  
This reduces the stress concentrations within the valve, and also is less disruptive to 
blood flow.  The leaflets are thicker at the base where they attach to the tubular body of 
the valve, and taper to a smaller thickness towards the lumen of the valve.  The leaflet 




This is the first flexible prosthetic vein valve having two leaflets that seal with significant 
surface contact area contained within a tube with a flared inlet and outlet to facilitate 
circumferential sealing.  The valve’s leaflets are not pre-opened, are non-parabolic in 
shape, and meet in surface sealing contact, thus creating a robust sealing mechanism.  
The valve can be manufactured from a single material, in a simple molding operation, 
and can be implanted by various methods, including stenting, using hooks or barbs, or 
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suturing techniques.  The valve is flexible, unlike stiff cardiac valves containing metal 
that can erode through a vein wall, and will comply with tortuous venous anatomy.  It 
will adapt to the elliptical cross-section of veins, as well as vein distention.  The valve 
will impose minimal radial stress on vein walls compared to prior art describing radially 
expanding stiff valves.  The valve design is unique by itself, and coupled with a material 
that has demonstrated low thrombogenecity properties, has potential to perform well in 
















Figure 26: Proximal view, or outlet, of valve (left) and distal view, or inlet, of valve 








Figure 27: Isometric view of valve die, with gates added to inlet and outlet to facilitate 
injection molding.   
 
 
       
 
Figure 28: Proximal outlet view of valve die with gates (left) and distal inlet view of 
valve die with gates (right). 
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Risk Analysis 
In the heavily regulated medical device industry, comprehensive risk analysis is 
necessary to demonstrate strict design control when developing an implantable medical 
device.  A design tool known as an FMEA, or Failure Modes Effects Analysis, is one 
method for assessing and mitigating risk.  Other risk analysis techniques include FMECA 
(Failure Modes Effects Criticality Analysis) and FTA (Fault Tree Analysis).  Between 
June 1, 1997, and June 1, 1998, the FDA inspected over 500 medical devices for design 
controls, and discovered that about 75% of the firms used one or more of these three risk 
analysis techniques [49].  A FMEA is an effective bottom-up approach for risk analysis, 
albeit time-consuming.  An FTA is used as a top-down approach to risk analysis, and is 
used by branching out causality modes of an undesired event using logic gates.   
 
Generally, FMEA’s are used for Class II and Class III medical devices, which are devices 
that pose the most risk to the patient in the event of failure.  A FMEA organizes the many 
possible events that could occur during the operation of a product, potentially affecting 
the functionality of the device and the safety of the consumer.  A FMEA examines each 
risk event with respect to three aspects, severity, occurrence, and detection, and assigns a 
score to the event for each category.  Scoring metrics can be found in Tables 10 - 12.  
Subsequently, an RPN (Risk Priority Number) is calculated by multiplying the three 
scores together. This score assesses how severe an event is, how often it could happen, 
and how easy it would be to detect.  The RPN number is then used to prioritize and 
mitigate risk elements.  While there are not any strict metrics used to score each risk 
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event, for this research an RPN value over 25 was considered to be a significant risk 
event, warranting corrective action.   
 
A FMEA was used to assess the risk of the valve’s design and manufacturing with 
relation to three main clinical functional modes: valve patency, valve retention, and valve 
competency (Figures 29-31).  This is a brief version of what a true product design FMEA 
developed at a medical device company would entail.  Emphasis was placed on the most 









Very High Death or serious injury likely without prompt medical 
intervention.  Death may be imminent. 
5 
High Patient has moderate or chronic clinical symptoms in 
response to significantly decreased performance and is 
associated with mild concern for patient safety. (ie., 
continued severe swelling, ulcerations, severe 
varicosities, bleeding, dizziness, shortness of breath) 
4 
Moderate Patient may present with mild or intermittent clinical 
symptoms indicative of slightly reduced performance. 
Patient safety has not been compromised and product 
continues to function in the intended manner. (ie., some 
swelling, mild pain, mild varicosities, discomfort) 
3 
Low Clinician may have an isolated test finding supporting 
decreased product performance but patient is 
asymptomatic. Alternatively, patient may claim 
symptoms without clinical findings. 
2 











Very Low Patient unaware of product malfunction.  Trained 
clinician unable to detect malfunction.  Surgical 
intervention may be required to detect malfunction. 
5 
Low Patient unaware of product malfunction.  Trained 
clinician unlikely to detect malfunction without an 
ascending or descending venogram 
4 
Moderate Patient unlikely aware of malfunction.  Clinician may 
require targeted investigation (Doppler ultrasound, air 
plethysmography) to discern problem.  
3 
High Patient may be aware of malfunction.  Clinician aware of 
malfunction following routine examination.   
2 
Very High Patient fully aware of product malfunction. (ie., clinical 
symptoms present). Alternatively, physician may easily 










Likely Incidence significantly more than 20%. 5 
Probable Incidence approximately 5-20%. 4 
Possible Incidence approximately 1-5%. 3 
Remote Incidence less than 1%.  Occurrence contingent upon 
implant error, patient anomaly, or other unlikely event.  
2 
Unlikely Incidence less than 0.1%. 1 
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3 24 None at this 
time 





ration > 2 
4 16 None at this 
time 
        4 Blood clots in 
leaflet pockets 
3 Proper material 
selection - 
preclinical trial 




        4 Blood clots distal 
to orifice 
2 Proper material 
selection - 
preclinical trial 









4 Leaflets don't 
open 
2 Opening pressure 
testing, cyclic 
pressure testing 
3 24 None at this 
time 
        4 Blood clots in 
orifice 
3 Proper material 
selection - 
preclinical trial 








4 Leaflets don't 
open 
2 Opening pressure 
testing, cyclic 
pressure testing 
3 24 None at this 
time 
        4 Blood clots in 
orifice 
3 Proper material 
selection - 
preclinical trial 




      DVT 
formation 
4 Leaflets don't 
open 
2 Opening pressure 
testing, cyclic 
pressure testing 




        4 Blood clots in 
orifice 
3 Proper material 
selection - 
preclinical trial 
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4 Valve erodes 
through fixation 
mechanism 
2 Suture pull-out 
strength 
calculations 
4 32 Functional testing 
of valve with 
sutures in place 
        4 Sutures break 2 Suture pull-out 
strength 
calculations 
4 32 Functional testing 
of valve with 
sutures in place 
        4 Stent did not 
expand properly 
3 None 4 48 Functional testing 
of stent-delivery 






5 Valve erodes 
through fixation 
mechanism 
2 Suture pull-out 
strength 
4 40 Functional testing 
of valve with 
sutures in place 
        5 Sutures break 2 Suture pull-out 
strength 
4 40 Functional testing 
of valve with 
sutures in place 
        5 Stent did not 
expand properly 
3 None 4 60 Functional testing 
of stent-delivery 
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3 Proximal, cyclic, 
and burst pressure 
1 12 None at this 
time 
        4 Leaflet 
damage 
2 Proximal, cyclic, 
and burst pressure 
1 8 None at this 
time 
      Varicosities 3 Poor 
leaflet 
coaption 
3 Proximal, cyclic, 
and burst pressure 
1 9 None at this 
time 
        3 Leaflet 
damage 
2 Proximal, cyclic, 
and burst pressure 
1 6 None at this 
time 





3 Proximal, cyclic, 
and burst pressure 
1 9 None at this 
time 
        3 Leaflet 
damage 
2 Proximal, cyclic, 
and burst pressure 
1 6 None at this 
time 






2 Proximal, cyclic, 
and burst pressure 
1 8 None at this 
time 




3 Proximal, cyclic, 
and burst pressure 
1 12 None at this 
time 
      Varicosities 3 Sutures 
break 
5 Proximal, cyclic, 
and burst pressure 
1 15 None at this 
time 




5 Proximal, cyclic, 
and burst pressure 
1 15 None at this 
time 




5 Proximal, cyclic, 
and burst pressure 
1 15 None at this 
time 




5 Proximal, cyclic, 
and burst pressure 
1 15 None at this 
time 
 
Figure 31: Design FMEA for valve competency 
 
 
Risk Mitigation  
Potential failure events with an RPN score larger than 25 are highlighted in orange as 
areas of significant risk.  Risk events above this threshold require some sort of 
preeminent action, via testing, further device development, or re-design.  RPN scores 
between 20 and 25 were highlighted in yellow as items that should be noticed as lower 
risk potential failure modes, but do not require further development or testing at this time.  
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Failure modes that have RPN numbers below 20 were de-prioritized, having been 
addressed through prior engineering analysis or testing.   
 
From the FMEA, it is clear that higher risk of failure is associated with valve patency and 
retention, and not valve competency.  The functional tests designed and conducted in this 
research address act as design controls for many of the potential failure modes.  However, 
for those failure modes having highest levels of risk, there are several additional 
corrective action items that are recommended to help mitigate risk (Table 13). 
 
 
Table 13: Mitigation strategies for high risk failure modes 
 





32-48 Flow studies should be examined with various 
orifice opening sizes to characterize the valve’s 
inefficiency due to pressure loss. 
An animal study will help demonstrated the valve’s 
performance with regards to thrombotic occlusions 
impeding flow.  An animal study has been planned 
for the summer of 2006.   
Full obstruction 
of valve orifice 
32-48 An animal study will help demonstrated the valve’s 
performance with regards to thrombotic occlusions 
impeding flow.  An animal study has been planned 
for the summer of 2006.   
Valve migration 32-60 Extensive testing should be carried out to examine 
implantation and fixation methods for the valve.  
These tests should include quantifiable data 
reflecting the pullout strength of sutures, stents, 
hooks, or barbs in veins.  The battery of tests can 
include mechanical bench testing, in vitro studies of 
the valve implanted into excised veins, cadaver 




Because this research concentrates on valve operation after implantation, studying the 
risk associated with the valve implantation procedure was considered outside of the scope 
of this work.  However, just as a Design FMEA was conducted on the valve’s design, a 
Process FMEA should eventually be conducted on both the manufacturing of the valve, 
as well as the implantation of the valve.  These tools will help identify additional failure 





Valve Die Manufacturing 
The prosthetic valves are comprised of 15% poly(vinyl-alcohol) hydrogel, manufactured 
per U.S. Patent 5,981,826.  Valves were fabricated by injecting PVA into a two-part 
silicone cavity mold, and subjecting the valves to a freeze-thaw curing process.   
 
Using the final CAD designs of the valves, a set of four extrusions was created on both 
the inlet and the outlet of the valve, to act as gates during the injection molding process.  
Valve dies (Figure 32) were made using stereolithography (SLA) (Quickparts.com, 
Atlanta, GA), a rapid-prototyping technique, using STL files derived from CAD files.  
The material used for SLA was Somos 8110 (DSM Somos, Elgin, Illinois) a semi-
flexible plastic material.   The resolution of the fabricated valve was 0.013 mm.  During 
rapid-prototyping, the valves were orientated with the longitudinal axis orthogonal to the 
resin pool during laser curing.  This was important for manufacturing the valves, since 
the construction of the leaflets required a vertical orientation for substrate support.  Semi-
flexibility was required of the material so that the SLA dies could be removed from the 
cavity molds without damaging either the dies or the molds.   
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The SLA valves acted as the positive die for making two-part cavity molds of the valve.  
Four silicone cavity molds were made of Sylgard 184®, a silicone elastomer, (Dow 
Corning, Midland, Michigan).  The molds needed to be comprised of a flexible material, 
so that the SLA dies as well as the PVA valves could be removed easily.  Silicone was 
used as mold material for its elastic properties, its biocompatibility, and its transparency.  
Prior to pouring molds around the SLA valves, the SLA valves were coated with a thin 
layer of 5% PVA solution, with each coat allowed to air dry for approximately 4 hours.  
This thin coating was required to prevent a phenomenon known as inhibition from 
occurring to the silicone.  Inhibition is an event that involves poor curing of a two-part 
silicone material.  When exposed to certain plastics, silicone may not cure, and such was 
the case with Somos 8110.  The thin coating of PVA prevented this problem.  The 
coating did not significantly alter the dimensions or tolerances of the valve.  In fact, the 
coating smoothened out the miniscule ridges that result from SLA resin layering, 
minimizing the effect of sharp edges on the valve. 
 
The coated SLA valves were placed in plastic mold wells.  The mixed silicone was 
poured around the SLA dies until it reached about three fourths of the height of the SLA 
dies.  To remove the large air pocket underneath the die’s cusps, the die was grasped and 
angled with forceps while in the liquid silicone mixture to allow the air bubble to float 
out.  A vacuum of 0.06 MPa gauge was applied for about 5 minutes to remove air 
bubbles from the silicone.  Subsequently, the molds were allowed to cure at ambient 
temperature for 12 hours, and then cured in an oven at 37 °C for 3 hours.  After cooling, a 
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thin film of mold release agent was applied on the top of the silicone half to facilitate 
mold separation, and allowed to dry for 30 minutes.  The silicone pouring and curing 
process was then repeated for creating the top half of the mold.  The plastic mold well 
was cut and removed, and the mold halves were gently pulled apart, exposing the valve 








Test valves were created by injecting liquid 15% PVA solution at approximately 80 °C 
temperature into the silicone mold with a 60 cc syringe.  The PVA was injected into the 
gates on the bottom of the mold.  Warm temperatures reduced the viscosity of PVA 
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solution, and made injection molding much more manageable.  It was observed that 
higher pressure and velocity of injection aided in distributing the solution throughout the 
mold cavity, and reduced air-bubble presence in the finished product.  The seven open 
gates on each valve allowed air to vent from the cavity as PVA was injected into the 
eighth gate.   
 
Valve Curing: Freeze-Thaw cycles 
The PVA valves were cured via a freezing and thawing process, effectively cross-linking 
the polymer to create a solid gel.  One freeze-thaw cycle consisted of freezing the molds 
containing PVA for 12 ± 0.5 hours at -15 °C.  The molds were then removed from the 
freezer and were left to thaw at ambient conditions for 3 ± 0.5 hours.  The molds wer 
loosely wrapped in damp cloth to prevent the hydrogel from drying.  Each successive 
freeze thaw cycle increased the number of cross-links within the hydrogel, thereby 
increasing its bulk elastic modulus.  Hydrogels generally swell in the presence of water, 
and if not stiff enough, will collapse and deform under its own weight.  Thus, the valves 
were kept within the molds during each freeze-thaw cycle to maintain dimension and 
form.   
 
Valve Removal and Final Processing 
After the molds were thawed sufficiently, the mold halves were gently pulled part, 
exposing the valves and the flash created during manufacturing.  Flash is excess material 
on a molded part formed because of mold gates or parting lines.  The valves were 
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removed very carefully from the molds by using light pulsed air pressure applied to the 
gates to pop the valves loose.  Excess flash was trimmed carefully, and valves were 
selected from each batch of 16 for their quality.  Quality was assessed primarily based on 
porosity, holes, completed parts, and homogeneity of the material.  Part rejection rate was 
approximately 25%.   
 
 
      
 
Figure 35: Silicone mold with excess PVA flash (left).  Silicone mold with flash 
removed (right); note that the mold contains 4 cavities for fabricate 4 valves at the same 
time.  The white translucent cylindrical objects within the mold are the valves. 
 
 
      
 
Figure 36: Silicone mold with top half removed, exposing the valves and flash (left).  
Silicone mold halves with flash removed from valve ends (right). 
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Figure 37: Silicone mold halves with valves, top view (right).  Silicone mold halves with 
valves, side view (right). 
 
      
 
Figure 38: Silicone mold half with valve removed, top view (left).  Silicone mold half 
with three valves; note the leaflets are joined and do not have an orifice (right). 
 
 
For selected valves, the orifice was cut open with surgical scissors, to thus transform the 
sealed valve into a bi-leaflet valve (Figure 39).  This was a critical step in fabricating a 
functioning valve.  The cutting techniques were practiced on about 20 scrapped valves to 
obtain consistency.  The function of the valves depended significantly on the accuracy 
and quality of cut.  True quality of cut could not be easily assessed without functional 
testing, thus screening of valves for testing occurred during initial testing.  Valves that 
were assessed to be potentially functional were stored in the molds to retain dimensions, 
and the molds were submerged in a water bath to keep the hydrogel moist.     
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Figure 39: Surgical scissors were used to cut the orifice.  The cutting process took about 




      
 
Figure 40: Valve in the close position (orifice has already been cut); note the faint line 
along the center of the valve where the leaflets meet to seal (left).  Valve in the open 




      
 
Figure 41: Side view of the valve, revealing its flared inlet and outlet for better 
circumferential sealing (left).  Isometric view of the valve; separate leaflets are 
distinguished by the orifice line (right) 
 
Vein-like Tube Fabrication 
A flexible prosthetic valve must accommodate the dynamic environment of native veins.  
A vein-like tube was needed to provide an appropriate test environment for the valve, and 
to mimic vein mechanics during physiologic loading.  It was important to re-create sinus 
expansion and vein distention proximal to the valve during applied proximal pressure.   A 
15% PVA hydrogel was used as the material of choice for this particular test application. 
Various other materials were considered for flexible tube test beds, including silicone 
elastomers, Tigon ® tubing, and excised distal porcine vena cava.  In feasibility 
fabrication, silicone tended to be too brittle, and was difficult to extract from molds 
without becoming damaged.  Tigon tubing was too stiff, which prevented any noticeable 
sinus expansion at low applied pressure.  Porcine vena cava were excised from adult farm 
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pigs (Holifield Farms, Porterdale, Georgia) at an abattoir, within 20 minutes of death.  
However, the vein samples were not ideal for cyclic testing, since biologic veins tend to 
retain reasonable mechanical properties for only a few days; and cyclic testing would last 
over five days.   
 
The hydrogel tubes had a 10 mm inner diameter, a 12 mm outer diameter, and a 1 mm 
thickness.  The tubes were made by pouring 15% poly(vinyl-alcohol) solution into 
machined molds with end-caps, and undergoing one freeze-thaw cycle.  The tubes were 
approximately 7 cm long, and were examined closely for porosity, gross non-uniformity 
or in-homogeneity before used in testing.   
 
      
 
Figure 42: Exploded view of tube (translucent cylinder) and the mold components used 
to make the tube (left).  Vein-like tube after one freeze-thaw cycle (right) 
 
 
Fixation of Valves in Tubes 
The valves needed to be fixed into the vein-like tubes in a manner simulating an 
implanted prosthetic valve.  Ideally, an implanted prosthetic valve would promote some 
degree of intimal formation from the vein, such that tissue would grow into the outer 
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periphery of the valve, similar to in-growth for Dacron ® vascular grafts.  (while PVA 
generally doesn’t elicit an intimal response, Dacron® could be integrated into the 
periphery of the valve to promote tissue growth.  Appropriate tissue in-growth does two 
main things for a vascular prosthetic. First, it secures the prosthetic in place and prevents 
migration.  Second, it seals the outer circumference of the prosthetic, so that blood flow 
will be channeled primarily only though the intended orifice.   
 
Thus, for testing, the valves needed to be fixed in a manner that secured the valves in the 
tube, yet also prevented circumferential leaking.  This was accomplished by using liquid 
15% PVA solution as glue.  The viscous solution was applied by brush into the lumen of 
the tube at ambient temperature.  The valve was placed inside and positioned 
appropriately, and additional solution was applied at the line joints where the valve inlet 
and outlet interfaced with the tube wall (Figure 43).  Tubes containing valves were then 
subjected to two freeze-thaw cycles (Figure 44), and the valves were effectively fixed in 
place and ready for testing.  The test specimens were stored in pink dyed water in plastic 
vials prior to testing (Figure 44).  The pink color provided greater contrast for visually 
inspecting the valve’s leaflets inside the tube.  Hereafter, tubes containing valves will be 
referred to as test specimens.   
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Figure 43: Vein-like tube and valve (left).  Valve inserted into vein-like tube, and fixed 
with 15% solution of PVA (right). 
 
 
      
 
Figure 44: Test specimen after 2 additional freeze thaw cycles, still in frozen state (left).  
Test specimen tied onto fitting for pressure testing, after completely thawing, and being 






Test specimens of both 3 freeze-thaw and 5 freeze-thaw cycles were subjected to the 
same test protocol.   Tests were performed specifically to evaluate the valve based on 
critical design specifications.  To summarize, design criteria included that the valve:  
 
1) open with a distal pressure gradient less than 5 mmHg,   
 
2) withstand backpressure of 300 mmHg with less than 1.0 mL/min of leakage, and 
 
3) withstand 500,000 cycles of opening and closing while meeting or exceeding design 
specifications 1 and 2.   
 
Table 14 briefly describes the various tests (detailed methodology is found in subsequent 
text).  Figure 45 describes in a flow chart the general test protocol for evaluating valve 
functionality.   
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Table 14: Brief description of function tests and their purposes 
 




This test evaluates what distal pressure gradient is required to 
open the valve leaflets and allow antegrade (forward) flow. 
Test B 
Reflux Leakage  
This test evaluates what amount of leakage, if any, the valve 
allows when proximal pressure is applied. 
Test C  
Second Opening 
Pressure 
This test is performed in the same manner as Test A.  
However, this test examines the effect of high sustained 
backpressure on the valve’s ability to open again. 
Test D  
Cyclic Life 
Functionality 
This test evaluates the valve’s cyclic life functionality by 
opening and closing the valve in physiologically-simulated 
conditions thousands of times.   
Test E  
Burst Pressure 
This test demonstrates the proximal pressure at which the 
valve will fail and cause excessive leakage. 
Failure analysis 
 
This analysis consisted of a qualitative approach for examining 
failure modes in valves that did not meet design criteria.  This 
analysis was conducted primarily for valves that failed Tests A 
and B and valves that underwent Test E.  However, analysis 
was performed on a few good valves as well, to compare 














Initial opening pressure 
test (antegrade) 
Test B 
























Cyclic life testing 








A few good valves  
Failure analysis – to compare 
good valves to bad valves 
Test specimen 
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Flow Media Selection 
Water was used as the test media.  Since bulk pressure was the parameter of primary 
concern for all three design criteria, the impact of viscosity on valve performance was 
considered negligible in this research.  Unlike glycerol-water mixtures that are often used 
to mimic blood’s viscosity and density, plain water facilitated easier cleanup of the valve 
and flow-loop.  Additionally, since vein valve operation is primarily pressure-driven and 
not flow driven [20, 51], water was a reasonable medium to use for testing.  During all 
hydrostatic and hydrodynamic testing, the specimens were kept wet with moist cloth, to 
prevent the hydrogel from drying.   
 
Preparation for Test A (Opening pressure) and Test B (Reflux Leakage)  
Test specimens were placed in a flow setup with a hand-operated syringe pump to 
evaluate valve performance for design criteria 1 and 2.  For all hydrostatic testing, the test 
specimens were orientated horizontally, at the same height as the pressure transducer and 
syringe pump, to negate the effects of gravity on pressure readings.  The leaflets were 
orientated so that the commissural line was orthogonal to the plane of the table that tests 
were conducted on. A pressure transducer (Harvard Apparatus, South Natick, 
Massachusetts) was placed in line with the syringe and specimen, and was calibrated 
periodically with a hydrostatic water column.  During testing, hand-syringe techniques 
were used to apply proximal and distal hydrostatic pressure to the specimens.  Constant 
applied pressure was needed in order to effectively measure the valve’s functional 
performance.  Valve performance varied with manufacturing quality, and a hand-syringe 
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pump technique created an effective controlled method to maintain this constant applied 
pressure.  Techniques were practiced prior to testing to achieve consistency and accuracy.   
 
Test A – Initial Opening Pressure Test 
Opening pressure was measured first, using dyed water for better leaflet visualization.  
The test specimens were secured onto a plastic fitting by tying a 2-0 Vicryl suture 
(Ethicon, Inc, Somerville, NJ).  A rubber o-ring was present between the plastic fitting 
and specimen tube.  The specimen was orientated such that the distal end of the valve 
was closest to the syringe, and the proximal end was facing the ambient atmosphere 
(Figure 46).  Pressure was applied using the hand-operated syringe in 1 mmHg 
increments, and held for approximately 5 seconds at each increment.  During 
pressurization, the valve was monitored for the instance of valve opening.  Valve opening 
was defined as occurring when dyed water became first noticeable on the proximal side 
of the leaflets, and the pressure was recorded when this event occurred.  After each 
opening, pressure was reduced to 0 mmHg, and water was removed from the proximal 
portion of the specimen with a pipette and absorbent cloth.  Five independent 
measurements were taken for opening pressure, one minute apart from each other.  One 
minute was allowed to pass between each measurement to relieve the valve of 
viscoelastic effects from the prior test.  Opening pressure testing occurred before testing 
for reflux leakage, and then again afterwards, to quantify any functional differences from 









Test B - Reflux leakage 
Reflux leakage was measured by applying proximal pressure on the valve and measuring 
the volume of water that leaked through the leaflets.  For this test, the specimen was 
reversed in orientation in the setup.  The proximal end of the valve faced the syringe 
pump, and the distal end was exposed to the ambient atmosphere (Figure 47).  An 18 mm 
inner diameter clear plastic tube was placed around the specimen to restrict its diameter 
distention to only 1.5 times its original diameter.  This was done to mimic venous 
distention, since veins distend to about 1.5 to 1.6 times their original diameter in vivo 
[12, 13].  Proximal pressure was applied from 0 mmHg to 300 mmHg, in increments of 
approximately 18 to 20 mmHg.  At each pressure step, pressure was applied in a ramp 
fashion from 0 mmHg to the desired step condition in a span of 5 seconds, and then held 
at a constant value for a total duration of 30 seconds.  Leakage was collected in a non-
wettable container, and measured using a 2.5 cc medical-grade syringe with needle to 
gather the water droplets.  This was an effective process for ensuring that all the leakage 
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was collected for measurement.  Approximately one minute elapsed between testing at 
each pressure step.  One minute was allowed to pass between each measurement to 
relieve the valve of viscoelastic effects from the prior test.   
 
 
Figure 47: Diagram of hydrostatic pressure test-setup for testing proximal pressure and 
reflux leakage (top view) 
 
 
From these measurements, a leak-rate value for each pressure level could be calculated, 
with units of mL/minute.  As opposed to one minute, a test duration of 30 seconds was 
used for measuring leak-rate because it was practical and did not sacrifice the quality of 
valve assessment.  At high pressures, the vein-like tube would expand considerably in 
diameter.  This caused much of the water volume in the syringe pump to be transferred to 
the newly expanded volume of the test specimen.  Because the syringe pump was limited 
in capacity to 10 cc, excessive leakage of low-performing valves would result in the 
remaining syringe volume being drained before one minute could surpass.  A larger 
capacity syringe would solve this problem; however, a larger syringe would also result in 
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less control in maintaining constant pressure, a critical requirement for testing.  Thus, it 






Figure 48: Hydrostatic pressure test-setup for testing proximal pressure and reflux 
leakage.  Specimen shown is B3-8-T9, exposed to approximately 300 mmHg of proximal 
pressure with no leakage present.  An 18 mm inner diameter clear plastic tube was placed 






Figure 49: Test specimen B3-8-T9 exposed to approximately 300 mmHg of proximal 
pressure with no leakage present.  Note the 18 mm plastic tube used to limit the sinus 




Test C – Second Opening Pressure Test 
After exposing the valve to high proximal pressures during the proximal pressure test, the 
valve’s opening pressure was again evaluated.  This test was conducted to characterize 
any change in the valve’s performance after being exposed to severe pressure conditions.  
Because PVA is a viscoelastic material, it was important to observe the effects of high 
proximal pressure loading on the valve’s ability to still open at low pressure gradients.  
Each second opening pressure test was performed within 3 minutes of completing the 
proximal pressure test.  The second opening pressure test was required for all valves that 
demonstrated good or excellent proximal pressure test results.  It was not performed or 
required for valves that were deemed bad.  Valves that had high leakage had problems of 
Valve site
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leaflet coaption, and this would make the opening pressure of the valve seem lower than 
it should have been. The same setup for Test A, the initial opening pressure test, was used 
for this test. 
 
Test D – Cyclic Life Testing 
After initially evaluating the valve’s hydrostatic performance, the test specimen was 
placed in a cyclic flow loop, designed to open and close the valve numerous times in 
simulated physiologic conditions.  The specimen was tied in place with 2-0 Vicryl sutures 
and placed in a water bath, and covered with absorbent paper cloth.  The water bath and 
paper cloth kept the hydrogel specimen from drying over the course of the days cyclic 
testing would occur.  The valve was orientated such that the proximal end was facing 
upwards, exposed to the pressure of the water column above it, thus mimicking a leg vein 
valve (Figure 50).    
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Figure 50: Hydrodynamic flow loop for evaluating cyclic life functionality (right).  




Physiologically, native vein valves open and close synchronously with calf muscle 
contractions.  During normal walking, calf compression propels 10 to 20 mL of blood 
through the veins, and compression occurs about 40 times a minute (0.67 Hz) during 
normal cadence [8, 9].  The primary requirement during cyclic testing was that the valve 
opened and closed in a periodic, identifiable fashion.  Correspondingly, multiple 
Masterflex ® Easy-Load ® rotary phase pumps were placed in parallel, using 24 gauge 
(8.0 mm) silicone tubing (Masterflex, Cole-Parmer Instrument Company, Vernon Hills, 
IL), to displace a total of approximately 10 mL of water with each stroke through the 




frequency and volume of blood flow during calf compression in normal walking cadence.  
The total net flow of water was 450 ± 30 mL/min.  The velocity of the water was not of 
primary concern in this research, since the aims of this research were to demonstrate 
pressure functionality of the valve.  
 
The flow loop was designed so that hydrostatic pressure was maintained proximal to the 
valve at 50 ± 5 mmHg, similar to physiologic conditions proximal to an adult common 
femoral vein.  Tested specimens were evaluated for functional performance at various 
points during the cyclic testing, generally every 50,000 to 60,000 cycles (about 24 hours).  
Nearly 1.5 hours were required to remove the valve from the setup, test for opening 
pressure and reflux leakage, and place the valve back into the setup, and it was 
reasonable from a time standpoint to only evaluate the valve every 24 hours.  At each 
measurement interval, the test specimen was removed from the loop and exposed to 
hydrostatic testing.  This testing quantified the valve’s functionality with respect to reflux 
leak-rate performance and opening pressure characteristics at various stages of life cyclic 
testing.   
 
Test E – Burst Pressure Testing 
Burst pressure testing characterized the maximum pressure at which valves would remain 
competent, prior to excessive leakage or structural damage.  Burst pressure testing was 
only conducted on valves that demonstrated functionality in prior hydrostatic testing.  A 
total of 5 valves underwent burst pressure testing.  Each specimen slated for this test was 
placed into the same hand-operated syringe pump setup used for testing reflux leakage.  
 107
An 18 mm inner diameter tube was placed around the specimen to restrict its diameter 
distention to only 1.5 times its original diameter.  The specimen with restrictive tube was 
inserted into the mouth of a clear flask orientated horizontally.  The flask was included in 





Figure 51: Test setup for burst pressure testing was similar to hydrostatic proximal 
pressure testing, with an addition of a glass flask to contain bursting water. 
 
 
The valve was pressured at a rate of approximately 50 mmHg per second.  A fast rate of 
pressurization was used to examine how the valve would respond to this type of loading.  
Fast pressurization occurs in humans during a sudden transition from sitting to standing, 
or during exercise.  Thus, burst pressure testing attempted to mimic this loading.  A 
mechanical syringe pump was not used in this case because existing equipment would not 
apply proximal pressure at a fast enough rate.   
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A digital camera was used to record video footage of the test specimen and pressure 
transducer reading simultaneously.  Of the five valves that were pressurized, video 
recording was only available for four.  Each video was later analyzed to determine the 
pressure at which water first leaked from each test specimen.  After valve failure, the 
specimens were inspected to determine the specific mode of failure. 
 
Failure Analysis 
Qualitative failure analysis was conducted to determine the failure mode of valves that 
did not demonstrate functionality during initial testing.  The valve leaflets were of 
primary concern during failure analysis, as they were the most critical design features that 
affected the pressure performance of the valve.  Failed specimens were dissected to 
expose the leaflets for visualization.  Each specimen tube was cut in the longitudinal 
direction (similar to a venotomy) from end to end, along the plane of leaflet coaption.  
The tubes were then spread open on a wax board.  Several drops of dilute red dye was 
applied to the exposed leaflets and allowed to soak into the hydrogel for 10 seconds 
before being wiped away.  This provided greater contrast in the hydrogel for better 
visualization of surface roughness, pitting, or other defects.  Digital pictures were taken 







REVIEW OF TEST PROCEDURES 
Five tests were conducted to determine if the prosthetic vein valve met the critical design 
specifications for bench testing.  These criteria are summarized in Table 15.   
 
 




Parameter Design Specification 
1 Patency The pressure gradient required to open the valve and 
cause forward fluid flow must be less than 5 mmHg. 
2 Competency Valve must structurally bear at least 300 mmHg of 
static pressure and must not leak more than 1.0 
mL/minute for all tested pressure from 0 to 300 
mmHg. 
3 Cyclic life 
functionality 
The valve must open and close in simulated 
physiologic conditions for at least 500,000 cycles, 
and continue to meet design specifications 1 and 2 at 




Table 16: Summary of the tests conducted 
 




This test evaluates what distal pressure gradient is required to 
open the valve leaflets and allow antegrade (forward) flow. 
Test B 
Reflux Leakage  
This test evaluates what amount of leakage, if any, the valve 
allows when proximal pressure is applied. 
Test C  
Second Opening 
Pressure 
This test is performed in the same manner as Test A.  
However, this test examines the effect of high sustained 
backpressure on the valve’s ability to open again. 
Test D  
Cyclic life 
functionality 
This test evaluates the valve’s cyclic life functionality by 
opening and closing the valve in physiologically-simulated 
conditions thousands of times.   
Test E  
Burst pressure 
This test demonstrates the proximal pressure at which the 
valve will fail and cause excessive leakage. 
Failure analysis 
 
This analysis consisted of a qualitative approach for examining 
failure modes in valves that did not meet design criteria.  This 
analysis was conducted primarily for valves that failed Tests A 
and B and valves that underwent Test E.  However, analysis 
was performed on a few good valves as well, to compare 
qualitatively good valves to bad valves.   
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TEST A (OPENING PRESSURE) RESULTS 
 

















after reflux testing 
(mmHg) 
3 B1-8-T9 2.6 ± 0.7 Excellent 3.7 ± 0.7 
3 A3-8-T9 3.7 ± 0.7 Excellent 4.5 ± 0.7 
3 D1-7-T8 2.3 ± 0.7 Excellent 5.0 ± 0.7 
3 B2-8-T9 3.3 ± 0.7 Excellent 7.3 ± 1.0 
3 B3-8-T9 2.4 ± 0.7 Good 8.5 ± 1.3* 
3 A4-8-T9 3.0 ± 0.5 Bad Not tested 
3 A1-8-T9 2.6 ± 0.7 Bad Not tested 
3 C2-7-T8 1.4 ± 0.7 Bad Not relevant 
3 D2-7-T8 1.6 ± 0.6 Bad Not relevant 
3 C1-7-T8 2.0 ± 0.5 Bad Not tested 
3 A2-8-T9 2.2 ± 0.7 Bad Not tested 
*Valve experienced 400 mmHg of backpressure prior to second opening pressure test, 






















after reflux testing 
(mmHg) 
5 D1-9-T10 3.7 ± 0.7 Excellent 4.5 ± 0.7 
5 C4-9-T10 2.8 ± 0.7 Excellent 4.0 ± 0.9 
5 C2-4-T5 4.1 ± 0.7 Excellent Not tested 
5 C1-9-T10 2.0 ± 0.5 Good 3.7 ± 0.7 
5 B3-9-T10 2.0 ± 0.5 Good 6.9 ± 0.7 
5 D3-4-T5 3.9 ± 0.7 Good Not tested 
5 B1-4-T6 6.4 ± 1.8 Good 9.4 ± 1.1 
5 C1-4-T5 5.1 ± 0.6 Bad Not tested 
5 A2-4-T6 6.0 ± 0.9 Bad Not tested 
5 D3-9-T10 2.6 ± 0.6 Bad Not tested 
5 D4-9-T10 2.4 ± 0.6 Bad Not tested 








Figures 52 - 62 depict the reflux leak-rate performance during proximal pressure testing 
for individual valves fabricated using 3 freeze-thaw cycles.  Leak-rates were recorded 
from 0 mmHg to 300 mmHg.  In cases where leak-rate exceeded 2.0 mL/min, the test 
was terminated, and leak-rate data was not acquired at higher pressures.  The design 
requirement for proximal pressure performance was that the valve does not exceed 1.0 
mL/min of reflux leakage at any applied proximal pressure from 0 to 300 mmHg.  
Excellent valves were valves having leak-rates equivalent or less than 0.5 mL/min.  Good 
valves were valves that had leak-rates that met the design criteria.  Bad valves had 
leakage greater than the design criteria. 
 
 
   Table 19: Description of categorizing valve competency 
 
Valve Categorization Description of criteria 
Excellent Leak-rate <  0.5 mL/min 
Good 0.5 mL/min < Leak-rate < 1.0 mL/min 






Excellent valve: reflux leak-rate performance met design 































Excellent valve: reflux leak-rate performance met design 



























Figure 53: Competency assessment of 3 cycle valve (A3-8-T9) 
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Excellent valve: reflux leak-rate performance met design 































Excellent valve: reflux leak-rate performance met design criteria 



























Figure 55: Competency assessment of 3 cycle valve (B2-8-T9) 
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Good valve: reflux leak-rate performance met design criteria by 
























































Figure 57: Competency assessment of 3 cycle valve (A4-8-T9) 
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Figure 59: Competency assessment of 3 cycle valve (C2-7-T8) 
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Figure 61: Competency assessment of 3 cycle valve (C1-7-T8) 
 118





































Figures 63 - 74 depict the reflux leak-rate performance during proximal pressure testing 
for individual valves fabricated using 5 freeze-thaw cycles.  Leak-rates were recorded 
from 0 mmHg to 300 mmHg.  In cases where leak-rate exceeded 2.0 mL/min, the test 
was terminated, and leak-rate data was not acquired at higher pressures.  The design 
requirement for proximal pressure performance was that the valve does not exceed 1.0 
mL/min of reflux leakage at any applied proximal pressure from 0 to 300 mmHg.  
Excellent valves were valves having leak-rates equivalent or less than 0.5 mL/min.  Good 
valves were valves having leak-rates that met the design criteria.  Bad valves had leakage 
greater than the design criteria. 
 
 
  Table 20: Description of categorizing valve competency 
 
Valve Categorization Description of criteria 
Excellent Leak-rate <  0.5 mL/min 
Good 0.5 mL/min < Leak-rate < 1.0 mL/min 








Excellent valve: reflux leak-rate performance met design 































Excellent valve: reflux leak-rate performance met design 



























Figure 64: Competency assessment of 5 cycle valve (C4-9-T10) 
 121


























































Figure 66: Competency assessment of 5 cycle valve (B3-9-T10) 
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Excellent Valve: Reflux leakage met design requirment and was 































Good valve: reflux leak-rate met design criteria and was less than 



























Figure 68: Competency assessment of 5 cycle valve (D3-4-T5) 
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Figure 70: Competency assessment of 5 cycle valve (C1-4-T5) 
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Figure 72: Competency assessment of 5 cycle valve (D3-9-T10) 
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Figure 74:  Competency assessment of 5 cycle valve (D2-9-T10) 
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TEST D (CYCLIC LIFE FUNCTIONALITY) RESULTS FOR 3 FREEZE-THAW 
CYCLE VALVE  
 
Table 21 and Figure 75 depict the opening pressure of a 3 freeze-thaw cycle valve 
throughout cyclic life testing.  Figures 76 – 82 depict the competency of the valve 
throughout cyclic life testing.   
 
Table 21: Opening pressure throughout cyclic life testing for a 3 freeze-thaw cycle valve 
(specimen B2-8-T9) 
 
Approximate # of  
open-close cycles 
Initial opening pressure 
(mmHg) 
Opening pressure after 
reflux testing (mmHg) 
0 (Initial test) 3.3 ± 0.7 7.3 ± 1.0 
68,000 2.6 ± 0.7 4.7 ± 1.0 
136,000 3.5 ± 0.5 4.3 ± 0.7 
193,000 3.5 ± 0.7 5.3 ± 0.7 
253,000 3.7 ± 0.7 5.3 ± 0.7 
385,000 4.3 ± 0.7 3.9 ± 0.7 
508,000 3.3 ± 0.7 3.3 ± 0.7 
 
 





































Figure 75: Valve opening pressures for a 3 freeze-thaw cycle valve measured before 
reflux testing met design criteria throughout cyclic life testing.  High reflux pressure (300 
mmHg) sustained for 30 seconds increased the valve’s opening pressure early during the 
valve’s cyclic life testing. 
 127
Excellent valve: reflux leak-rate performance met design criteria 



























Figure 76: Prior to cyclic life testing, a 3 freeze-thaw cycle valve met a key design 
































Figure 77: After approximately 70,000 open-close cycles, a 3 freeze-thaw cycle valve 
met a key design criterion of having less than 1 mL/min of leak-rate (specimen B2-8-T9). 
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Figure 78: After approximately 135,000 open-close cycles, a 3 freeze-thaw cycle valve 
































Figure 79: After approximately 190,000 open-close cycles, a 3 freeze-thaw cycle valve 
met a key design criterion of having less than 1 mL/min of leak-rate (specimen B2-8-T9). 
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Figure 80: After approximately 250,000 open-close cycles, a 3 freeze-thaw cycle valve 
































Figure 81: After approximately 385,000 open-close cycles, a 3 freeze-thaw cycle valve 
met a key design criterion of having less than 1 mL/min of leak-rate (specimen B2-8-T9). 
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Figure 82: After 500,000 open-close cycles, a 3 freeze-thaw cycle valve met a key 
design criterion of having less than 1 mL/min of leak-rate (specimen B2-8-T9).  An 
“excellent” valve like B2-8-T9 (3 freeze-thaw cycles) maintained excellent leak-rate 
characteristics even after 500,000 open-close cycles.  This excellent performance can be 
attributed to the valve being in excellent condition prior to any cyclic testing.  Cyclic 
testing was terminated after this evaluation of the valve because test equipment began to 
break.  The test was not terminated because of the valve. 
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TEST D (CYCLIC LIFE FUNCTIONALITY) RESULTS FOR 5 FREEZE-THAW 
CYCLE VALVE 
 
Table 22 and Figure 83 depict the opening pressure of a 5 freeze-thaw cycle throughout 
cyclic life testing.  Figures 84 – 90 depict the competency of the valve throughout cyclic 
life testing.   
 
Table 22: Opening pressure throughout cyclic life testing (D3-4-T5) for a 5 freeze-thaw 
cycle valve 
 
Approximate # of 
open-close cycles 
Initial opening pressure 
(mmHg) 
Opening pressure after 
reflux testing (mmHg) 
0 (Initial test) 3.9 ± 0.7 NA 
27,000 2.7 ± 0.5 5.3 ± 1.2 
62,000 2.5 ± 0.7 5.0 ± 0.7 
124,000 2.7 ± 0.8 3.9 ± 0.7 
182,000 2.8 ± 0.6 4.0 ± 0.7 
244,000 2.8 ± 0.6 6.0 ± 0.9 
295,000* 2.0 ± 0.6 NA 
*Test terminated after 295,000 cycles 
 


































Figure 83: Valve opening pressures for a 5 freeze-thaw cycle valve measured before 
reflux testing met design criteria throughout cyclic life testing.  High reflux pressure (300 
mmHg) sustained for 30 seconds increased the valve’s opening pressure. 
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Figure 84: Prior to any cyclic testing, a 5 freeze-thaw cycle valve met a key design 
criterion of having less than 1 mL/min of leak-rate (specimen D3-4-T5). 
 
 



























Figure 85: After 27,000 open-close cycles, a 5 freeze-thaw cycle valve met a key design 
criterion of having less than 1 mL/min of leak-rate (specimen D3-4-T5). 
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Figure 86: After nearly 62,000 open-close cycles, a 5 freeze-thaw cycle valve met the 































Figure 87: After nearly 124,000 open-close cycles, a 5 freeze-thaw cycle valve met the 
leak-rate criterion for proximal pressures less than 200 mmHg (specimen D3-4-T5). 
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Figure 88: After approximately 182,000 open-close cycles, a 5 freeze-thaw cycle valve 































Figure 89: After approximately 244,000 open-close cycles, a 5 freeze-thaw cycle valve 
met the leak-rate criterion for proximal pressures less than 280 mmHg (specimen D3-4-
T5). 
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Figure 90: After approximately 295,000 open-close cycles, a 5 freeze-thaw cycle valve 




The degradation in reflux performance is most likely due to initial deformities in the 
leaflet sealing area.  At 0 cycles, this valve was only “good” and not “excellent,” 
allowing leak-rates between 0.5 and 1.0 mL/min at proximal pressures greater than 200 
mmHg.  Cracks or leaflet surface defects probably prevented the valve from being 
“excellent.” Thus, over the span of 295,000 cycles, existing cracks or surface defects 
probably worsened, as an increase in leak-rate was evident from 0 cycles to 295,000 
cycles.  Still, after 295,000 cycles, this valve is functionally competent for physiologic 
conditions, where proximal pressure is typically 35 to 50 mmHg. 
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However, an “excellent” valve like B2-8-T9 (3 freeze-thaw cycles) maintained excellent 
leak-rate characteristics even until over 500,000 open-close cycles.  This excellent 
performance can be attributed to the valve being in excellent condition prior to any cyclic 
testing.  It is presumed it would take longer for an “excellent” valve to lose competency 
than for a “good” valve to lose competency.  The two sets of cyclic life data (B2-8-T9 
and D3-4-T5) demonstrates that valve manufacturing was the main culprit in causing the 
valve to lose functionality, an aspect that can easily be addressed with commercial 
manufacturing techniques.     
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TEST E (BURST PRESSURE) RESULTS 
 
 
The valve failed in maintaining competency at an applied proximal pressure of 530 ± 10 
mmHg.  This burst pressure is six times greater than physiologic proximal pressure.  Five 
valves were tested under burst-pressure conditions.  Only valves that had demonstrated 
good or excellent competency were subjected to burst pressure testing.  One valve burst 
at 940 ± 10 mmHg of backpressure, failing by a leaflet tear.  The four remaining valve 
did not incur any visible or significant damage to the leaflets when examined during 
failure analysis.  It is hypothesized that two of the valves failed due to leaflet prolapse or 
folding.  The final two valves failed by circumferential leakage; the PVA “glue” used to 
fix the valves into the tubes was not sufficiently applied.  A leak-path propagated along 
the circumference of the valve, starting at the proximal end of the valve, and spreading to 
the distal end (Figure 99 and Figure 101).  Although the sample size was not large 
enough to determine significant difference in burst pressure of 3 versus 5 freeze-cycle 
valves, it does not appear there is a noticeable advantage in burst pressure capabilities.   
 
 
Table 23:  Burst pressure test results 
 
Cycles Specimen Leak-rate Burst Pressure Failure Mode 
3 B1-8-T9 Excellent 940 ± 10 mmHg Leaflet tear 
3 D1-7-T8 Excellent 740 ± 10 mmHg Leaflet prolapse 
3 B3-8-T9 Good 530 ± 10 mmHg Leaflet prolapse 
5 C4-9-T10 Excellent 860 ± 10 mmHg 66% circumference blowout 







FAILURE ANALYSIS RESULTS 
 
Table 24: Failure analysis results 
 
Cycles Valve Leak-rate Status Failure Mode 
3 B1-8-T9 Excellent Burst testing Leaflet tear 
3 A3-8-T9 Excellent Reserved NA 
3 D1-7-T8 Excellent Burst testing Leaflet prolapse 
3 B2-8-T9 Excellent Cyclic life testing None, lasted 508,000 cycles 
3 B3-8-T9 Good Burst testing Leaflet prolapse 
3 A4-8-T9 Bad Cut for analysis Surface roughness 
3 A1-8-T9 Bad Cut for analysis Severe pitting 
3 C2-7-T8 Bad Cut for analysis Hole in right leaflet 
3 D2-7-T8 Bad Cut for analysis Hole in right leaflet 
3 C1-7-T8 Bad Cut for analysis Hole in left leaflet 
3 A2-8-T9 Bad Cut for analysis Surface roughness 
 
 
Cycles Valve Leak-rate Status Failure Mode 
5 D1-9-T10 Excellent Reserved NA 
5 C4-9-T10 Excellent Burst testing 66% circumference blowout 
5 C2-4-T5 Excellent Cut for analysis None 
5 C1-9-T10 Good Burst testing 50% circumference blowout 
5 B3-9-T10 Good Cut for analysis None 
5 D3-4-T5 Good Cyclic life testing None, lasted 295,000 cycles 
5 B1-4-T6 Good Reserved NA 
5 C1-4-T5 Bad Reserved NA 
5 A2-4-T6 Bad Reserved NA 
5 D3-9-T10 Bad Cut for analysis Surface roughness 
5 D4-9-T10 Bad Cut for analysis Surface roughness 











Figure 91: Comparison of human femoral vein valve afflicted with primary 
incompetence (top) [22], human femoral vein valve that is normal (middle) [22], and a 
good prosthetic vein valve fabricated in this research (bottom) 
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Valve ID B1-8-T9 
Freeze-thaw cycles 3 
Leak-rate performance Excellent 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure  4) burst pressure testing 
Failure mode Leaflet tear; valve burst at 940 ± 10 mmHg 
 
 




Valve ID A4-8-T9 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode Leaflet surface roughness 
 
 
Figure 93:  Qualitative failure analysis of valve leaflets (specimen A4-8-T9) 
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Valve ID A1-8-T9 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) 
opening pressure 
Failure mode Leaflet surface roughness 
 





Valve ID C2-7-T8 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode Leaflet hole, leaflet surface roughness 
 
Figure 95:  Qualitative failure analysis of valve leaflets (specimen C2-7-T8) 
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Valve ID D2-7-T8 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) 
opening pressure 
Failure mode Leaflet hole 
 





Valve ID C1-7-T8 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) 
opening pressure 
Failure mode Leaflet hole 
 
Figure 97:  Qualitative failure analysis of valve leaflets (specimen C1-7-T8) 
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Valve ID A2-8-T9 
Freeze-thaw cycles 3 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode Leaflet surface roughness (near point of coaption) 
 




Valve ID C4-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Excellent 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 4) burst pressure 
Failure mode 66% of the circumferential seal was compromised, 
resulting in circumferential leakage 
 
Figure 99:  Qualitative failure analysis of valve leaflets (specimen C4-9-T10)
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Valve ID C2-4-T5 
Freeze-thaw cycles 5 
Leak-rate performance Excellent 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode None; the valve is free from holes and has a relatively 
smooth sealing surface 
 
 
Figure 100:  Qualitative failure analysis of valve leaflets (specimen C2-4-T5) 
 
 
Valve ID C1-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Good 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure  4) burst pressure 
Failure mode 50% circumference seal blowout, resulting in 
circumferential leakage.  Leaflets were intact, and sealing 
surface was relatively smooth. 
 
 
Figure 101:  Qualitative failure analysis of valve leaflets (specimen C1-9-T10) 
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Valve ID B3-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Good 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode None, but gouge in right leaflet was present.  This may 
attribute to why the leak-rate for this valve throughout 
proximal testing was equivalent or slightly less than 1.0 
mL/min, rather than other good or excellent valves that 
performed much better. 
 
 
Figure 102:  Qualitative failure analysis of valve leaflets (specimen B3-9-T10) 
 
 
Valve ID D3-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode Leaflet surface roughness – mismatched sealing surfaces 
 
 
Figure 103:  Qualitative failure analysis of valve leaflets (specimen D3-9-T10) 
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Valve ID D4-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode Leaflet surface roughness – pitting near tube wall 
 
 




Valve ID D2-9-T10 
Freeze-thaw cycles 5 
Leak-rate performance Bad 
Test history 1) opening pressure  2) reflux pressure  3) opening 
pressure 
Failure mode  
 
 
Figure 105:  Qualitative failure analysis of valve leaflets (specimen D2-9-T10) 
 147
SUMMARY OF RESULTS 
 
The novel prosthetic valve met the three critical design criteria specified earlier in this 
thesis.  The valve opens with a pressure gradient less than 5 mmHg, withstands 300 
mmHg of backpressure while having no greater than 1.0 mL leakage per minute, and 
maintains this functionality even after opening and closing over 500,000 times.  The 
valve failed at a burst pressure of 530 ± 10 mmHg, a pressure six times greater than 
physiologic proximal pressure.  The valve’s design concept has demonstrated itself as a 
clinically relevant functional design.   
 
Of 11 test valves fabricated using 3 freeze-thaw cycles, five showed excellent or good 
competency results.  Valves that demonstrated leak-rate performance meeting the leak-
rate design criteria (leak-rate less than or equivalent to 1.0 mL/min) were deemed as 
“good valves.”  Valves demonstrating better performance, having leak-rates equivalent to 
or less than 0.5 mL/min were deemed “excellent valves.”  Valves exceeding the leak-rate 
design criteria were labeled as “bad valves.”  This categorization of valves determined 
how the valves would be processed for failure analysis after testing.   
 
Amongst the 3 freeze-thaw cycle valves that exhibited good or excellent competency 
results, the average initial opening pressure was 2.9 ± 1.6 mmHg.  The average opening 
pressure for the valve design increased to 5.1 ± 2 mmHg after being exposed to very high 
proximal pressure (300 mmHg).  The six valves that failed proximal pressure testing 
underwent failure analysis, and all failures could be attributed to abnormalities in 
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manufacturing.  Abnormalities included torn leaflets, excessive leaflet porosity, and 
leaflet surface roughness due to incorrect cutting of the leaflet orifice.  These 
abnormalities showed that the valve did not fail because of design aspects, but because of 
limited manufacturing capabilities in a lab setting (manufacturing success was about 
45%).  Despite manufacturing limitations, the valve design met all design criteria for 
opening pressure and reflux leakage.  One 3 freeze-thaw cycle valve underwent cyclic 
testing and continued to be functional after 500,000 cycles of opening and closing.   
 
Of 12 test valves fabricated using 5 freeze-thaw cycles, seven showed excellent or good 
results.  Of these seven valves, the average initial opening pressure was 3.6 ± 2.4 mmHg.  
The average opening pressure for the valve design increased to 5.7 ± 1.9 mmHg after 
being exposed to very high proximal pressure (300 mmHg).  Failure analysis was 
performed on three of the valves that failed proximal pressure testing.  All three failures 
could be attributed to abnormalities in manufacturing.  Abnormalities involved excessive 
leaflet surface roughness due to incorrect cutting of the leaflet commissure.  
Manufacturing success was 58%, evidenced by 7 of 12 valves showing good or excellent 
proximal pressure performance.  One 5 freeze-thaw cycle valve underwent cyclic testing 









ANALYSIS OF TEST RESULTS 
 




















for fresh valve 
at 287 mmHg; 
40 mL/min for 
fixed valve at 
287 mmHg 
Tested in a pulsatile 
flow loop, but no 
pressure results 
reported 
Not tested Vein that the 








4.5 mmHg Not tested Water perfused at 
120/80 mmHg at 60 
bpm for 47 days – 
no quantitative test 
results reported 
Not tested Not specified 




1 mmHg Withstood 300 
mmHg, but no 
leak-rate 
reported 
Not tested Not tested Rigid plastic 
tube 







Not reported After 5 months, no 
significant damage 
to mechanical valves 





2.9 ± 1.6 
mmHg 











Test A: Initial Opening Pressure 
The 3 freeze-thaw cycle prosthetic vein valve opened with an average pressure of 2.9 ± 
1.6 mmHg, which meets the design criteria for opening pressure.  This opening pressure 
is largely dependent on the elastic modulus of the leaflets, the leaflet angle, and 
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particularly the leaflet thickness.  The leaflet thickness in the valves tested in this 
research was approximately 0.7 mm, which is rather large compared to the 0.05 mm 
thickness that most natural human vein valve leaflets have [14].  The 0.7 mm thickness 
was necessary for manufacturing the valve in a lab setting; thinner leaflets would be more 
difficult to cut with surgical scissors to create the orifice.  However, if the valve were 
manufactured using expensive equipment with higher precision and accuracy, the valve 
leaflets could be made much thinner without sacrificing quality.  The reduction in leaflet 
thickness should reduce the opening pressure of the valve.  It would be reasonable to 
expect opening pressures around 1.0 mmHg after refining the valve leaflet thickness, and 
still maintain valve competency at high proximal pressures.   
 
The Pellethane® valve developed by Hill et al opened at a pressure of 4.5 mmHg.  
However, no data was reported regarding the pressure performance of the valve after 
subjected to multiple cycles of opening and closing or after subjected to high sustained 
backpressure.  The authors reported problems of patency due to thrombus formation in 
most of the occluded valves; all Pellethane® valves had occluded within 8 days of 
surgery. 
 
Compared to prior studies, DeLaria et al developed a more comprehensive approach in 
evaluating a prosthetic vein valve’s performance.  They examined prosthetic vein valves 
with a more physiologically relevant flow loop, and conducted reflux leakage testing.  
They did report opening pressures of 1 mmHg for valves for gluteraldehyde-fixed bovine 
jugular veins; however, the valve leaflets were fixed in a slightly pre-opened position, 
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and opening pressure is really not a relevant parameter to measure for a pre-opened 
valve. 
 
Pavcnik et al created a SIS valve that opens with a pressure gradient of 1 mmHg [33].  
This valve demonstrated very good opening pressure characteristics in bench testing, and 
has shown good promise as a prosthetic vein valve.  However, the valve seemed sensitive 
to correct placement and implantation; approximately one-third of valves that were 
slightly tilted in the vein or placed in tortuous anatomy caused thrombus formation [33, 
35].  Excessive thrombus formation often leads to an occluded or incompetent valve.  
Any type or design of prosthetic valve could be adversely affected by incorrect placement 
or poor implantation technique.  However, a valve can be designed such that its 
performance is less sensitive to human error or improbable events.   
 
The valve presented in this research has been designed to minimize the potential for 
skewing in a vein by having a length-diameter ratio close to or greater than 2.  When 
placing these valves into the vein-like tubes for specimen preparation, it was observed 
that there was very little opportunity for the valve to skew.  However, skewing will also 
be a function of correct sizing for the vein, as well as local expansions in the vein wall.  It 
will be prudent for future work to include delivery and implantation techniques to assess 
the valve’s alignment, placement, and retention.   
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Test B: Reflux Leakage 
The prosthetic valve presented in this research demonstrated the ability to withstand 300 
mmHg of applied proximal pressure with leak-rate less than 0.5 mL/min.  This is a very 
good result compared to prior prosthetic valve studies.  For example, DeLaria et al 
applied 287 mmHg of proximal pressure on fresh and gluteraldehyde-fixed bovine 
jugular vein valves, which resulted in 120 mL/min and 40 mL/min reflux leak-rates, 
respectively [31].  These leak-rates are very high compared to the prosthetic vein valve 
developed in this research.  Also, introducing bovine valves into humans may cause 
immunogenic responses. 
 
The square-stent SIS vein valve developed by Pavcnik et al demonstrated the ability to 
withstand 300 mmHg in a rigid plastic tube.  However, no leak-rate data was reported, 
and thus it is difficult to quantitatively assess this valve’s competency in high proximal 
pressure conditions.  Also, a rigid plastic tube does not mimic the mechanics and 
compliance of a human vein as well as a flexible tube.  It would be interesting to examine 
the SIS valve’s competency in a dynamic, high proximal pressure environment.  The 
authors did conduct descending venograms of their valve in a sheep model and 
demonstrated competency, which showed potential of their valve a prosthetic substitute 
with respect to competency at low proximal pressures.  Competency performance at high 
proximal pressure has not yet been reported.   
 
Hill et al and Taheri et al did not report conducting tests to examine reflux leakage.  
Also, while DeLaria et al observed sinus expansion in the bovine valves, the other three 
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studies did not account for the elasticity of natural human veins.  An implanted prosthetic 
valve will be subject to various intramuscular pressures, tortuous anatomy, and dynamic 
changes in vein diameter.  Thus, a prosthetic valve should be tested in an environment 
that mimics venous function.  This involves mimicking venous distention and also sinus 
expansion.  Figure 106 shows that the vein-like tubes used in this research mimicked 
venous distention behavior, while Figure 107 shows sinus expansion similar to a biologic 
vein valve.   
 























Synthetic vein-like tube (3
freeze-thaw cycles)
Proximal Human Saphenous
Vein, from Stooker et al,
2003
Human Saphenous Vein,
from Wesley et al, 1975
 
 
Figure 106: Synthetic vein-like tube for testing valves displayed similar compliance and 
diameter distention behavior to natural human leg veins.  Distension was limited to about 
1.5 times the original diameter by the restrictive plastic tube placed around test 
specimens.  This graph was recreated in part using data from Wesley et al [12] and 




                
 
Figure 107: Prosthetic vein valve exposed to back pressures (R-L) : 0 mmHg, 90 mmHg, 
170 mmHg, and canine femoral vein valve exposed to 184 mmHg [52] (Far right).  Note 
the similarity in sinus distension between the artificial vein-like tube and the human vein.  
The vein-like tube simulated vein mechanics with respect to sinus expansion, and 




Test C: Second Opening Pressure 
This test was performed to assess whether the valve’s opening pressure characteristics 
would change after the valve was exposed to high sustained proximal pressures.  There 
was about a 2 mmHg increase (2.9 ± 1.6 mmHg to 5.1 ± 2.0 mmHg) in opening pressure, 
most probably due to the viscoelastic nature of PVA.  Such a test was not performed on 
prior prosthetic valves, so it is difficult to determine the relative performance of this 
valve.  It is clear that the initial opening pressure (from Test A) meets the design 
requirements for opening pressure.  The second opening pressure (from Test C) is border-
line with the design criteria.  Although the second opening pressure is a result from 
exposing the valve to extreme (300 mmHg) proximal pressure, it is nevertheless an area 
for improvement.  The second opening pressure can be lowered by creating leaflets that 
are thinner, and thus lowering both initial and second opening pressures.  Also, testing 
the valve at physiologic proximal pressures (35 to 50 mmHg) may provide a more 
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relevant prediction of second opening pressure.  Realistically, proximal pressure on the 
most proximal CFV valve will rarely exceed 120 mmHg for a sustained period of time.  
Exposing the valve to 300 mmHg and retesting opening pressure may be too aggressive 
of a test.  Regardless however, the second opening pressure of the valve is an important 
performance attribute of the valve, and work should be done to lower the second opening 
pressure.   
 
Test D: Cyclic life functionality 
This test demonstrated the novel prosthetic valve’s functionality at various points of 
cyclic life testing, including after the valve opened and closed more than 500,000 times.  
The test was terminated not because of any valve failure (the valve was still in excellent 
condition) but rather because the pump used in the test setup was beginning to wear.  The 
results indicated that the valve could withstand a reasonable lifespan and remain 
functioning.   
 
It is difficult to analyze the internal cracking or micro-damage induced on any 
engineering product in cyclic life testing without using destructive methods.  Because the 
number of valve specimens for testing was limited, destructive methods were not used, 
and thus data was not available for fatigue damage.  The next best method for 
determining the integrity of the valve was to use functional testing throughout cyclic life 
testing.  It was assumed that a valve that had poor structural integrity would not perform 
well in the functional tests.  This assumption held true, evidenced by identifying gross 
defects in “bad” valves during failure analysis.  However, the failure analysis was a 
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qualitative assessment of the valve’s structural integrity.  The next step for failure 
analysis would be to use quantify the porosity, cracking, and damage using destructive 
methods. 
 
It was clear from the failure analysis that the leaflets are the region of the valve most 
susceptible to damage.  As the leaflets are the most dynamic part of the valve, they are 
the attributes of the valve that should be analyzed further for structural integrity during 
cyclic testing.  Areas that may be susceptible to fatigue damage are hypothesized in 
Figure 108, based on the cyclic dynamics of the valve in those areas.  An accurate finite 
element model may provide a more quantitative assessment of stress and strains in the 
valve leaflets, as well as information about the effects of crack propagation and 
accumulated micro-damage on valve performance.   
 
      
 




Table 26: Comparison of cyclic flow loop test parameters 
 









DeLaria et al 
(bovine 
valves) 
670 ± 70 
mL/min 
0.2 Hz ~ 56 mL 30-45 
mmHg 
NA NA 





0.27 Hz ~ 19 mL 100 
mmHg 
5 months “little or no fatigue” 
Sathe 450 ± 30 
mL/min 








Both Taheri et al and DeLaria et al subjected their prosthetic valve to some sort of cyclic 
life testing.  Taheri et al used a phase pump that operated at 16 cycles/min to expose the 
valve to alternating proximal pressure of 100 mmHg in a flow-loop system [30].  The net 
flow was 300 mL/min.  The platinum and the pyrolitic carbon-covered titanium valves 
were tested for 5 months.  The study reported “little or no fatigue of materials.”  Metal 
valves can be expected to have reasonably long life, and demonstrate good cyclic fatigue 
performance.  However, a metallic valve in a venous environment imposes the risk of 
erosion through the vein, discomfort for the patient, and may cause unnecessary trauma 
to the vein.  The design of the metallic valve was likely an extension of heart valve 
design.  Blood flow in the heart is very different from blood flow in the venous system, 
and a heart valve may not be suitable for venous applications.   
 
DeLaria et al used a respiratory pump that operated 12 cycles/min, and expose their 
bovine jugular vein valves to proximal pressures ranging between 30 and 45 mmHg [31].  
The net flow was 670 ± 70 mL/min.  However, beyond placing the valve into a cyclic 
flow loop, little results were reported on the functionality of the valve during cyclic 
testing.  Also, the time duration of cyclic testing was not specified.  In light of this 
 158
absence of reported data, it seems that the loop was used more to evaluate the valve 
opening and closing characteristics during each pump of the calf rather than long term 
functionality.   
 
Test E: Burst Pressure 
To date there has been little work in characterizing the burst pressure of a prosthetic vein 
valve.  This research presents a prosthetic vein valve that withstood at least 530 ± 10 
mmHg of proximal pressure before leaking excessively.  This burst pressure is about six 
times greater than physiologic proximal pressure imposed on CFV valves.  Improved 
manufacturing of the valve will probably result in higher burst pressure.  In particular, 
quality issues related to porosity, material homogeneity, and composite structures will 
become important for future burst testing.   
 
Recommendations for additional testing 
This research proposed four test methods for evaluating the functionality of a prosthetic 
vein valve.  Test methods were developed for measuring opening pressure, reflux 
leakage, cyclic life, and also burst pressure.  These tests target the operational 
functionality of the valve that can expose failure mechanisms.  However, there are other 
tests that could be completed to gain additional insight into the valve’s performance.  For 
example, cyclic life testing occurred in physiologic conditions; to accelerate fatigue, 
cyclic life testing could be conducted with higher proximal pressure.  Also, simulating 
external pressure on the valve will mimic the intramuscular pressures a natural vein valve 
experiences.  This could be accomplished by surrounding the test specimen with a 
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pressure chamber.  Bench testing could also include manipulating and bending the valve 
to mimic the dynamic loading of a valve in tortuous anatomy.   
 
Bench testing should also evaluate the fixation methods used for the valve.  This research 
used PVA solution to “glue” the valve into the tube specimen.   It would be important to 
study how sutures, stents, or hooks or barbs will affect the performance and functionality 
of the valve.  Implantation and fixation techniques are discussed in the subsequent 
“Future Work” section.  Finally, tests should be created to study the valve’s impact on 
vascular biology.  Namely, thombogenecity and immunogenicity of the valve should be 




This research presents a new and novel implantable prosthetic vein valve.  This is the first 
flexible prosthetic vein valve having two leaflets that seal with significant surface contact 
area contained within a tube with a flared inlet and outlet to facilitate circumferential 
sealing.  The valve’s leaflets are not pre-opened, are non-parabolic in shape, and meet in 
surface sealing contact, thus creating a robust sealing mechanism.  The valve is flexible, 
unlike much of prior art describing rigid frameworks and metal struts, and thus will 
comply with tortuous venous anatomy.  It will adapt to the elliptical cross-section of 
veins, as well as vein distention.  The valve will impose minimal radial stress on vein 
walls compared to prior art describing radially expanding stiff valves.   
 
A provisional patent application has been filed with the U.S. Patent and Trademark 
Office (GTRC ID 3471).  This invention has the freedom to operate in a commercial 
setting.  There is no knowledge of infringement of prior art at the time this thesis is 
published.  Table 27 provides a comparison of the Sathe et al invention to the more 







Table 27: Sathe et al valve does not infringe on prior art 
 




Title + Description Main Claims Main differences with  
Sathe et al valve 




01/11/05 Implantable prosthetic 
valve Radially 
expanding, contains wire 
scaffold with leaflets 
composed of polymeric 
fibers, bovine pericardial 
tissue – multiple leaflet 
design (3 to 8) – 
specified to hold up to 
100 mmHg, open 
between 1 and 20 mmHg 
Generally cylindrical 
radially collapsible scaffold 
supporting collapsible leaf 
valves portion, with leaves 
constructed of metal frame 
and sealing lining.  Lining 
to be constructed of 
polymers, silk, or bovine 
pericardial tissue.  Valve 
leaves are flexibly hinged 
- metal framework for leaflets 
 
- valve leaflets contact each 
other with abutting edges as 
opposed to area contact 
 
- valve cusps have “open 




Wilder et al 
04/06/04 Venous valve and graft 
combination 
Three parabolic sections 
forming a trileaflet 
design.  Leaflets are 
attached inside a tube 
graft, and are suggested 
to be made of woven 
fibers, either warp or 
weft configuration, such 
as those knit types used 
in PET arterial grafts 
Synthetic, biocompatible 
material, with inner tube 
and outer tube, with inner 
tube forming three 
equivalent parabolic lobes 
that interface 
- Three or more cusps 
 
- inner and outer tube 
assembly 
 
- Cusps are approximately 
parabolic 
 
- tube is straight, has no flaring 










Table 27 (continued) 
 




Title + Description Main Claims Main differences with  
Sathe et al valve 
Diagram from patent filing 
6,494,909 
Greenhalgh 
12/17/02 Endovascular valve 
Plurality of leaflets (patent 
prefers two), formed 
within a tube of braided 
flexible filaments.  
Leaflets made of flexible 
material (does not specify).  
For higher pressure 
applications, patent 
suggests intermeshing 
longitudinal supports into 
the leaflets 
One-way valve having 
flexible tube formed of 
intermeshed filaments, 
collapsible within a 
catheter, formed into 
plurality of leaflets, with 
means of flexibly biasing 
leaflets together. 
Leaflets made of flexible 
membrane comprised of 
silicone layer. 
- Tube formed of braided 
intermeshed filaments 
 
- membranes composed of 
silicone layer 
 
- radial supports on both ends 
 






implantable venous valve 
Self-expanding wire-
structure, containing at 
least one leaflet (diagram 
depicts bileaflet design), 
preferably two, with valve 
cusps composed of a 
“duckbilled” shape 
Self-expandable vein 
valve with tubular metal 
wire support, containing 
at least two longitudinal 
struts, structured around 
at least one leaflet, with 
leaflets having wire frame 
and two eyelets, allowing 
leaflet to pivot to open 
and close.   
- leaflet pivots on two points of 
contact formed by metal wire 
loop eyelets 
 
- leaflet has internal support 
 
- tubular metal wire frame 




Moll et al 
09/11/01 Device for regulating the 
flow of blood through the 
blood system Tubular 
wire frame with shape 
memory alloy metal, 
containing several pockets 
(valve sinuses) for valve 
cusps  
A support frame 
configured to press 
outwards against vein 
wall, having at least one 
collapsible flow 
restriction pocket.  The 
support frame is generally 
tubular, and collapsible 
for catheter implantation. 
- metal wire support frame 
 









Table 27 (continued) 
 




Title + Description Main Claims Main differences with  
Sathe et al valve 
Diagram from patent filing 
6,562,069 
Cai et al 
05/13/03 Polymer leaflet designs 
for medical devices  
Flexible polymer leaflets 
connected to supporting 
ring and commissure 
protrusions – trileaflet 
design – St. Jude 
Medical 
Rigid stent support structure 
and plurality of flexible 
polymer leaflets and 
commissural supports.  
Polymer material selected 
from group of 
polyurethanes, silicones, 
and a few others (no 
hydrogels mentioned) 
- no tubular construct or 
housing 
 
- valve area in relaxed state 
is open at least 10 percent of 
luminal area 
 
- rigid support structure (not 
flexible) with scallops 
 





10/20/98 Vascular and venous 
valve implant 
prostheses Exovascular 
support device, acts like 
template in aiding 
implantation and 
transplantation of 
venous valves, also acts 
as dilation restrictor 
when implanted around 
vessel body (from 
Baxter, Inc) 
Vascular system for 
facilitating implantation of 
vascular graft, containing 
tubular exovascular stent, 
dilation restrictor with 
flanges to fit over the vessel.  
Endovascular venous valve 
prosthesis contains stent 
assembly, preserved vein 
segment, suture apertures 
for facilitating surgery.    
- chemically preserved vein 
segment containing a valve 
 
- exovascular stent support for 
facilitating surgical 
implantation of preserved 
valve 
 
- stent contains suture 
template for attachment of 









Design refinement  
Some improvements can be made to the valve’s leaflets, namely creating thinner leaflets 
for improved opening pressure performance.  However, thinner leaflets may pose more of 
a problem with cyclic life functionality or competency at high proximal pressures.  A 
compromise must be found, where opening pressure can be lowered without sacrificing 
competency or cyclic life.  Finite element modeling and further experimentation will be 
helpful to optimize leaflet thickness.  Also, the valve material could be made into a 
composite to help prevent accumulation of micro-damage, propagation of cracks, or 
cracking.  Interspersed filaments, fibers, or meshes may improve the long term structural 
integrity of the valve.  It is important to note that the valve leaflets need not be the same 
thickness of natural vein valves to be functional.  Mechanical heart valves look nothing 
like natural heart valves, yet still remain functional as a treatment for heart valve 
pathologies.  Similarly, a vein valve design can have leaflets that may be different from 
natural vein valves, provided that the prosthetic vein valve affords the same functionality 
as a native vein valve.   
 
Design for manufacturing 
There are a few design features that could be improved to help facilitate a high-yield 
manufacturing process.  The leaflets are the most complex feature of the valve, and will 
require accurate manufacturing processes to ensure good valve performance.  The design 
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worked well with injection molding during prototype development.  However, there were 
some problems with air bubbles becoming trapped in tight geometrical spaces.  The valve 
design should be adapted to include drafts and improved fillet radii to facilitate better 
flow of material during injection molding.    
 
If metal molds are to be used rather than silicone molds, then the metal molds will 
probably have to be machined.  The rough mold shape can be cast; however, special 
machining processes will be required to create small design features and angles in the 
metal mold.  Most likely, ball-end milling will be used to create the cavity molds.  This 
may require alterations in angles and curvatures, particularly in the valve pocket regions 
to allow the tool bit to fit into tight spaces.  There is some freedom in the design to allow 
the valve to be altered in shape to accommodate manufacturing needs.  The primary goal 
of the design is to remain operationally function, and there are various combinations of 
geometry changes that can be made while still attaining functionality.   
 
Improved manufacturing techniques for high production yields 
Precise manufacturing processes will greatly benefit the valve’s performance.  As this 
research has shown, the design concept works well.  Valves that had failed could be 
attributed to poor manufacturing techniques that caused leaflet tears, holes, or excessive 
leaflet surface roughness.  Thus, improved manufacturing should eliminate a majority of 
these failures, resulting in valves that perform consistently well.  The cutting of the 
orifice is a process that caused most variability in valve quality.  An alternative to cutting 
the commissural opening could be to use precision laser cutting.  A laser with a small 
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spot size will cut the leaflets in a non-contact manner, thus minimizing cutting variability 
associated with material elasticity.  A high-quality CO2 laser can cut a minimum width of 
100 to 150 microns, to a depth of several millimeters.  However, laser cutting the leaflets 
will not be an easy process to control.  Also, pressure testing would have to be conducted 
to determine if this gap in the leaflets would be acceptable to prevent reflux leakage.  A 
second alternative to create a good orifice is to create it in the molding process.  The 
molds could incorporate a thin rigid film to ace as a separator to keep the leaflets from 
binding against each other during valve curing.  However, the thin film or foil must be 
robust enough to withstand many molding cycles. 
 
The molds in this research were created of silicone for their low cost, ease for 
manufacturing, and transparency.  However, in a high yield manufacturing environment, 
the molds must be made such that dimensional tolerances will be small to reduce 
variability in the process.  Typically for medical device manufacturing, stainless steel is 
used for tooling because it will maintain its dimensions for a reasonable time period, and 
does not corrode easily.  High-quality machined stainless steel molds should be created 
for high-yield manufacturing.   
 
At some point, the manufacturing process should yield sterile, packaged valves.  This will 
be necessary to make prototypes for use in pre-clinical animal trials, and eventual human 
trials.  Sterilization of the valves will require adjustments in manufacturing tooling, 
processes, and quality control.  It is not easy to sterilize PVA, since a steam autoclave 
will melt the material, and a gas-plasma oxidizer will dehydrate the material.  Rinsing the 
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PVA valve in a chemical bath could be a sterilization option; however, residual chemicals 
should be removed prior to packaging, since certain chemicals may be toxic.   
 
Design for implantation 
While this research has focuses on designing a functional valve from an operational 
perspective, the valve must eventually be configured for implantation into human veins.  
This is a necessary step to help translate this technology from an engineering laboratory 
to a hospital operation room.  There are three modes of implantation that have been 
envisioned for this prosthetic valve.  The first involves a standard longitudinal venotomy 
of the affected vein, through which the valve can be inserted and pushed proximal of the 
venotomy by 1 or 2 cm.  The valve can then be fixed into place using 6-0 or 7-0 vicryl 
non-absorbable interrupted sutures.  However, the sutures will be blind, and thus subject 
to potential error.  To help combat these human factors, improvements should be made to 
the design to facilitated implantation.  For example, a slightly raised ring could be placed 
around the flared inlet and outlet of the valve, for the surgeon to feel through the vein 
wall.  This ring could serve as an anchor for sutures.  Or, the valve could incorporate a 
radiopaque tag or marker, or could be radio-luminescent so that the surgeon can visualize 
the valve using a fluoroscope.   
 
A second method for implanting the valve could be to conduct a standard transverse 
venotomy, severing the afflicted vein into two tubes.  The valve could be implanted to 
create an end-to-end anastamoses with the distal and proximal ends of the vein.  Suture 
placement would not be blind, and the surgeon could better affix the valve into place.  To 
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facilitate this end-to-end anastamoses implantion, the valve body could be designed to be 
longer to accommodate the resection of damaged vein walls.  The valve inlet and outlet 
could incorporate a Dacron® ring to facilitate neointimal sealing of the proximal and 
distal vein segments to the valve. 
 
The third method for implanting the valve would involve a more minimally invasive 
approach: catheter delivery.  This prosthetic valve is very flexible and is resistant to 
kinking, and can be packaged inside a catheter.  The catheter could access a distal vein 
branch of the afflicted vein, and thus could deliver the valve to the desired site.  There are 
several methods for fixing a catheter-delivered valve into place.  The first is using a 
balloon-expandable stent that is incorporated into the cylindrical body of the valve.  A 
self-expanding stent can also be used.  A third fixation method involves using hooks or 
barbs that are embedded in the valve’s body.  The hooks or barbs will catch into the vein 
wall, and will prevent the valve from migrating.  This fixation method is often used to 
keep a vena caval filter in place, so that it can continue to trap embolic debris in patients.  
However, issues of vein trauma should be examined - cyclic loading and pressurization of 
the valve may cause the hooks or barbs to tear the vein wall.   
 
Pre-clinical animal trial 
The valve has demonstrated functional performance in bench testing; the next phase of 
functional testing should involve a pre-clinical animal trial.  A short term feasibility study 
has been planned and submitted for IACUC (Institutional Animal Care and Use 
Committee) review to evaluate the valve’s thrombogencity and patency in a porcine 
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model.  Other animal models for future consideration could include ovine and canine 
models.  Good results from an animal trial could pave the path to eventual clinical studies 






This research defined key design specifications for a prosthetic vein valve to be 
considered functionally operational.  It was determined that the valve should 1) open with 
a pressure gradient less than 5 mmHg, withstand 300 mmHg of backpressure while 
having no greater than 1.0 mL leakage per minute, and maintain this functionality even 
after opening and closing over 500,000 times.  These design specifications were 
developed after examining consumer needs and focusing on the more critical operational 
requirements that would dictate the performance of the valve.   
 
This research developed physiologically relevant test methods for quantifying the 
operational functionality of a prosthetic vein valve.  Each test was designed to 
demonstrate the valve’s performance with respect to the design specifications.  Test A 
(initial opening pressure) and Test C (second opening pressure) demonstrated the patency 
of the valve for design criteria 1.  Test B (reflux leakage testing) and Test E (burst 
pressure testing) evaluated the competency of the valve for design criteria 2.  Test D 
(cyclic life testing) showed the valve’s functionality after numerous cycles of operation.  
Failure analysis then assessed structural quality of the valves, and linked any failures to 
distinct and identifiable problems from manufacturing.  The design of the valve was not 
an issue in valve failures.   
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The valve’s design concept has proven itself as a functional design via functional testing.  
The novel prosthetic valve met the three aforementioned critical design criteria.  The 
valve can open with a pressure gradient as low as 2.6 ± 0.7 mmHg (Specimen B1-8-T9).  
The valve can withstand 300 mmHg with a leak-rate less than 0.5 mL/min.  The valve 
can withstand over 500,000 cycles and still meet the design criteria for opening pressure 
and reflux leakage.  The valve design failed at a burst pressure of 530 ± 10 mmHg, a 
pressure six times greater than physiologic proximal pressure.  The valve presented in 
this research is operationally functional, and shows good potential as a solution to 
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